Back

Explore every episode of the podcast Ground Truths

Dive into the complete episode list for Ground Truths. Each episode is cataloged with detailed descriptions, making it easy to find and explore specific topics. Keep track of all episodes from your favorite podcast and never miss a moment of insightful content.

Rows per page:

1–50 of 100

TitlePub. DateDuration
Jo Chikwe: A Renowned Cardiac Surgeon, on Leadership, Diversity, And Much More15 nov. 202600:57:18

Prof Joanna Chikwe is Chair of the Department of Cardiac Surgery in the Smidt Heart Institute at Cedars-Sinai, one of the top heart centers in the United States, and a Professor at UCLA School of Medicine. She is also Editor-in-Chief of the Annals of Thoracic Surgery, the field’s most prestigious peer review journal. This year she was Chair of the Scientific Sessions of the 99th Annual Meeting of the American Heart Association (AHA). She is a recognized expert on mitral valve repair and a leader of a randomized trial that compares surgical repair with the mitral clip procedure, a catheter-based intervention. She is one of only a handful of Black female cardiac surgeons in the United States.

This conversation was recorded at the AHA national meeting in Chicago on November 8, 2026, with a live audience that asked many excellent questions. It is the first Ground Truths in front of a live audience, and hopefully more to come. None of my questions were provided to Dr. Chikwe in advance.

Ground Truths has >217,000 subscribers from every US state and 214 countries. There are over 320,000 followers of Ground Truths so more than 100,000 folks who can easily convert to be free subscribers. If you’re one of them, please consider doing so.

Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you’re not a subscriber, please join!

If you found this interesting PLEASE share it!

The proceeds from all voluntary paid subscriptions go to support our summer internship program. It enabled us to accept and support a record number of 62 summer interns that joined us in 2026! These are high school, college and medical students selected from thousands of applicants. We couldn’t do this expanded program without the funds coming in through Ground Truths. Thank you!



Get full access to Ground Truths at erictopol.substack.com/subscribe
Ethan Mollick on AI: Where Are We Now and Where Are We Headed10 nov. 202600:56:02

Ethan Mollick is an Associate Professor at Wharton, University of Pennsylvania, head of their Generative AI Lab, and author of the new book CO-EXISTENCE, just released, and on the NY Times bestseller list right away. His prior book CO-INTELLIGENCE was also huge hit, NYT bestseller. He writes ONE USEFUL THING on Substack, which is one of the most insightful and popular series of essays on AI on the platform.

Let me highlight that Ethan evaluates all of the new models independently and is not funded by any of the AI companies, which puts him in a singular or rarified group of experts.

Here are some of the topics we discussed:

* The Jagged Frontier (the term Ethan came up with that has been adopted by all)

* The end of Prompting

* The Next-Token Train

* The Bitter Lesson

* Deskilling and Never Skilling

* Hyperscaling and Recursive Self-Improvement (RSI)

* Data Centers

* Claude Table 5.2 (his new essay with a mind blowing video not to miss)

* Safety of AI and Existential Threats

* Personal AI Agents (Muse and Dot)

* Education

* Science, Authorship, Peer Review

* Medical AI—Doctors out of the loop, AI potentially better than doctors with AI

* Ethan’s use of Agents (from his new essay)

About Ground Truths

This substack has more than 217,000 subscribers from every US state and 215 countries. There are over 320,000 followers of Ground Truths so more than 100,000 folks who can easily convert to be free subscribers. If you’re one of them, please consider doing so.

Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you’re not a subscriber, please join!

If you found this interesting PLEASE share it!

*

The proceeds from all voluntary paid subscriptions go to support our summer internship program. It enabled us to accept and support a record number of 62 summer interns that joined us in 2026! These are high school, college and medical students selected from thousands of applicants. We couldn’t do this expanded program without the funds coming in through Ground Truths. Thank you!

Thank you Malcolm MacPherson, Tobin Trevarthen, Rick (equity muse) Botelho, John Wills Lloyd, Arzu Najjar, and >700 others for tuning into my live video with Ethan Mollick! Join me for my next live video in the app.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Vadim Gladyshev and the Science of Aging27 oct. 202600:50:22

Vadim Gladyshev, PhD, Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School, elected to the National Academy of Science, is a prolific science of aging researcher. We covered many topics including:

—The nature of aging, and how it is different from biological aging (with glossary below)

—The clocks of biological aging, which he considers biomarkers

proteomic organ clock paper

transcriptomic clock paper

mAge (multimodal) clock with wearable preprint

facial clock (and others to come such as voice, videos)

metabolomic clock paper (from a different group)

—Transplant of heart from old to young and young to old (preprint) and Rejuvenation

Nature News and Views on that study by Chris Simms

And how this could markedly expand transplant donor organs

Parabiosis studies in mice

—Effect of drugs on biological aging

—slowing of biological aging with anti-fibrotic drug by proteomic clocks

—studies of semaglutide in 5 randomized trials vs placebo, organ proteomic clocks

—AI and aging biology

—Future of aging

Ground Truths has 217,000 subscribers from every US state and 214 countries. There are over 320,000 followers of Ground Truths so more than 100,000 folks who can easily convert to be free subscribers. If you’re one of them, please consider doing so.

Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you’re not a subscriber, please join!

If you found this interesting PLEASE share it!

The proceeds from all voluntary paid subscriptions go to support our summer internship program. It enabled us to accept and support a record number of 62 summer interns that joined us in 2026! These are high school, college and medical students selected from thousands of applicants. We couldn’t do this expanded program without the funds coming in through Ground Truths. Thank you!

And big thanks to jojofinance, VivoSage, Burak Yedek, Vau Geha, José Pedro Castro, and 800 others for tuning into my live video with Vadim Gladyshev! Join me for my next live video in the app. Impressive since we had technical audio issues for the first 10 minutes and the attendees rose from 500-800!

I edited out the video/audio the first 10 minutes when we couldn’t get started so you wouldn’t have to go through the horrible echo or silence while we waited for Vadim’s return.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Michael Lewis: The NIH “Murder Mystery,” DOGE, and Our Government Immune System06 oct. 202601:03:07

Michael Lewis is one of the best storytellers of our era. You know and likely have read his books Moneyball, The Big Short, The Blind Side, Flash Boys, Liar’s Poker, and The Undoing Project, to name a few. He has long been one of my favorite authors.

This was the first interview that Michael did on his new book, BLOCKERS, published on October 6th, streamed live on Substack Sept 29th. It’s his 21st book and 4 of the last 5 have been about the US government: The Fifth Risk (2019), Premonition (2021), and Who Is Government? (2025).

His ability to talk with the silent civil servant heroes of multiple government agencies (the Blockers), members of the DOGE destruction team, and much more from the current US government administration.

Here’s a gift link to the exclusive excerpt at WSJ

I won’t review all the things we discussed here, but the chapter on the NIH reads like an Agatha Christie murder mystery. We learned a whole different version of what happened that differed from what was previously reported.

Thank you jojofinance, Andrew Bowdle, Tracy Paeschke, MD, FACC, Bob Fleischman, Sean Stevenson, and many nearly 500 others for tuning into my live video with Michael Lewis! Join me for my next live video in the app.

Ground Truths has 217,000 subscribers from every US state and 214 countries. There are over 300,000 followers of Ground Truths so more than 100,000 folks who can easily convert to be free subscribers.

Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you’re not a subscriber, please join!

If you found this interesting PLEASE share it!

The proceeds from all voluntary paid subscriptions go to support our summer internship program. It enabled us to accept and support a record number of 62 summer interns that joined us in 2026! These are high school, college and medical students selected from thousands of applicants. We couldn’t do this expanded program without the funds coming in through Ground Truths. Thank you!



Get full access to Ground Truths at erictopol.substack.com/subscribe
Marios Georgakis: Why Did Two Major Clinical Trials for Heart Disease Fail?14 sept. 202601:08:22

In recent weeks the results (announced by press release) of 2 major placebo-controlled randomized trials—ZEUS, testing an interleukin-6 (IL-6) blocker vs inflammation, and HORIZON, testing a drug to lower Lp(a), indicated failure to achieve their primary endpoint.

Are we maxxed out for new treatments vs heart disease, as this article in the WSJ (←gift link) today asserts?

“Cardiovascular drug development is starting to look a bit like the modern oil industry. The easy wells have been tapped. What’s left is in deep water: expensive, technically perilous and less likely to strike oil.”

Or is it more complicated? Are the trial results and reasons for failure different?

I wrote a recent Ground Truths —The Coronary Artery Inflammation Controversy— on the data (what has been released to date) and my take. But I wanted to vet this with another physician-scientist who is studying atherosclerosis and turned to Prof Marios Georgakis, from the University of Munich, who as I mentioned in the previous piece, wrote a brilliant analysis of ZEUS and is also doing writing about HORIZON.

Many years ago we went through a “CV winter” when the biopharma companies largely shunned doing clinical trials for heart disease. They thought the field had been maxxed out. After a lapse of several years, there have many trials undertaken with positive results and substantial progress for better treatments vs heart disease. Both Marios and I remain optimistic that we are a long way from maxing out, as you’ll learn from the podcast. Heart disease is the number one global killer, for both men and women. That’s despite all the progress that has been made to date.

Thanks for your support of Ground Truths and to Dr. Julie Kellogg, Vau Geha, Ralph Horwitz, Jessica Coffman, Michael G. Levin, MD, and mopre than 400 others for tuning into my live video with Marios Georgakis!

**********************************

Ground Truths has 215,000 subscribers from every US state and 214 countries. There are over 310,000 followers of Ground Truths so nearly 100,000 folks who can easily convert to be free subscribers. Please consider doing that…it’s free.

Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you’re not a subscriber, please join!

If you found this interesting PLEASE share it!

The proceeds from all voluntary paid subscriptions go to support our summer internship program. It enabled us to accept and support a record number of 62 summer interns that joined us in 2026! These are high school, college and medical students selected from thousands of applicants. We couldn’t do this expanded program without the funds coming in through Ground Truths. Thank you!



Get full access to Ground Truths at erictopol.substack.com/subscribe
Two Landmark Studies Challenge Dogma About our Brain Immune Cells and Aging30 août 202600:44:06

This podcast is meant to complement my recent Ground Truths post Why Our Memory Slips After Age 50 which has all the relevant links to the 2 papers, key graphics, and other related publications. If you haven’t had a chance to read that, it would be helpful to spend a few minutes to do so before listening to this podcast.

Links to the 2 papers for those who don’t want to look back

Zemke et al in Science https://www.science.org/doi/10.1126/science.adt8307

Belk et al in Nature https://www.nature.com/articles/s41586-026-10939-0

It’s a major and fascinating discovery. We’re talking about a “hostile takeover” of blood monocyte cells that invade the brain and ultimately completely replace the brain microglia. The problem is these new microglia are pro-inflammatory.

A surprising finding is about CHIP (blood stem cells with mutations known as clonal hematopoiesis of indeterminate potential) that was shown to be protective. It’s surprising because CHIP is common with age and until now it has been linked to bad things such as cardiovascular disease, clotting, and cancer. If this pans out, it introduces the concept of immunotherapy of the blood (“brain immunotherapy”).

We discussed recent studies of microglia replacement and ways to keep our brain microglia intact, such as prevention any breakdown of the blood brain barrier.

The role of latent viruses and the mechanism of benefit of the Shingles vaccine were touched on.

Our conversation provides far more color and perspective about why their independent, complementary, and convergent findings are so important, debunking our longstanding belief that the microglia, the immune cells in the brain, are exclusively derived from the brain. Technology driven discovery. And what are the next steps in this line of research.

I hope you found this podcast illuminating and fun. If you did, plus share it with your network. Thanks for supporting Ground Truths and your help in spreading the word.

And thank to jojofinance, Elisabetta Pilotti, Daniel Rench, Dr. Sara Wolfson, Bob Fleischman, and hundreds of others for tuning into the live video with Julia Belk and Nathan Zemke! Join me for my next live video in the app.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Deborah Cohen: The Wellness-Industrial Complex23 août 202600:58:51

Deb Cohen is an award winning investigative journalist and correspondent who trained as a physician and has worked with the BBC and BMJ. She just published BAD INFLUENCE, a book which takes us deep into the wellness-industrial complex—the confluence of the supplement, testing, tech, and pharma industries, and how they sell health anxiety to healthy people.

Here are some of the points we discussed:

—The big market in healthy, well people. Tests, wearables, imaging, supplements, etc

—Algorithms feed the health anxiety in an amplifying, vicious loop on the social media platforms. When the algorithm knows you better than you.

—The special qualities of influencers, likable, relatable, vulnerable, appearance as friends, certainty, cultivating parasocial relationships. “I understand you, I see you, I hear you.” Often with financial conflicts of interest. Plus hidden financial benefits.

—The inverted pyramid of evidence and displacement of trust. Anecdotes believed and accepted as best evidence instead of rigorous randomized trials. A big flip, doctors losing trust to influencers and the sponsors of influencers.

—The Nocebo effect of harm through expectations

—The epidemic of neurologic tics during the pandemic traced back to TikTok, a viral contagion with 5.8 billion views (Figure made with Notebook LM)

—Potential for regulation of patient/consumers/prosumer influencers

—Celebrity influencers and the recent NEJM paper

—Many ideas for how we can mitigate this mess (Graphic by Notebook LM)

—Many illuminating patient examples: Femtech, silicon breast implant illness (BII), beta blocker experiment, a bogus bioresonance of hair test in a woman with GI symptoms, full-body MRI of brain lesions (transmitted to the patient by an automated message) that were a false positive.

—The term “wellness”

—Concierge physicians

Thank you jojofinance, Vote Against Billionaires, Gretchen Faucett, Mary Powers, Jessica Coffman, and hundreds of others for tuning into my live video with Bad Influence! Join me for my next live video in the app.

Ground Truths has subscribers from every US state and 214 countries. There are over 302,000 followers of Ground Truths so nearly 90,000 folks who can easily convert to be free subscribers.

Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you’re not a subscriber, please join!

If you found this interesting PLEASE share it!

A couple of other things to note:

—Thanks to the voluntary paid subscribers who support our summer internship program for high school, college, and grad school students. On August 6th, we had a poster session with our SRTI summer interns (pictured below) which was an extraordinary event with about 100 posters!

—I hit a publication milestone that I had not ever envisioned. More than 400,000 citations with an h-index of 259, as tallied by Google Scholar

Thanks to all for your support of Ground Truths.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Sarah Urbut: Predicting Your Health Arc04 août 202600:53:37

Sarah Urbut is a physician-scientist at Harvard Medical School and the Massachusetts General Research Institute. She and her colleagues published a landmark paper in Nature on patient health journeys for 3 different cohorts—the Mass General Brigham patients, the UK Biobank, and the All of Us research program—with a cumulative 683,000 individuals, 348 diseases, and up to 52 years of follow-up. Integrating electronic medical records and polygenic risk scores (N=36). An AI model was developed and validated called ALADYNOULLI, with each individual represented latent disease signatures (N=21), mathematically and biologically driven. An example of a patient’s dynamic life journey (health arc) is provided in the Figure below (adapted from the paper, made with NotebookLM). The longitudinal story for each individual is key here. Using a Gaussian process, the risk continually shifts like a GPS navigation when you make a wrong turn and you are re-routed. Considerable effort was dedicated to addressing selection bias with inverse probability weighting.

Here are 20 temporal pattern signatures for the UK Biobank cohort, which help to provide the biologic mechanism of a person’s disease, as shown for multiple conditions like heart attack, breast cancer, and depression. That is, the same disease phenotype can link to different genomic pathway underpinnings. An example for breast cancer could be related to signature 8 or signature 7; the latter tied to inflammation and metabolic abnormalities. This biological pattern could also be used to detect likely medication failure (such as SSRI treatment for depression) and predict rare diseases.

In fact, the model was used to discover genomic signatures for different diseases, as shown below.

This model predicted 1 and 10-year risk of diseases at the individual level and far surpassed routinely used clinical prediction calculators such as the pooled cohort equation (PCE) for coronary artery disease (0.89 vs 0.68, respectively, 1-year risk ) and the GAIL model for breast cancer (0.783 vs 0.54, respectively). ALADYNOULLI also surpassed accuracy for precision when compared with the recent Delphi-2M model that I wrote about here

The ALADYNOULLI paper is packed with information and equations and is not easy to get through without a sophisticated math background. That’s why the summary infographic below (made by Notebook LM) may be helpful to grasp its main findings

Prediction of Your Health Trajectory in Context

The new model substantively adds to many other recent reports that include Delphi 2M, APOLLO, and AURORA that predict future health events up to 20 years out. Each of these models were different with respect to inputs, how patient data were represented (tokens, embeddings, or latent states), and prediction outputs as briefly summarized in the Table I made below. Notably, the inputs are complementary and likely additive, such that the deeper and longer (longitudinally) the data re for each individual, the better predictive accuracy will be possible.

Adding to these models are many specific disease prediction (e.g. cancer, asthma, diabetes, neurodegenerative diseases) and sources of data (such as sleep lab, wearables, or high-throughput proteomics).

We are now seeing intense efforts at medical forecasting which will continue to evolve and something that was not previously possible in patient care. What I mean is that we could provide a rough sense of a patient’s risk for, let’s say Alzhiemer’s disease, but could not temporally place when it might occur. Age 65 or 95? It makes a huge difference. And so does the ability to apply counterfactuals, what-if scenarios for the individuals to reduce the risk, markedly defer a condition’s appearance, or even fully prevent it. That’s why ALADYNOULLI adds yet another dimension, different methodology, multiple patient cohorts, and novel findings that further add to a new prediction and prevention dimension of medical practice. It couldn’t have been done with multimodal AI.

Note to readers: I wrote this post entirely. There was no AI used except to generate 3 Figures by Notebook LM (Figure 1,3 and 4) as noted. Figure 2 above is from the Supplemental information of the paper. I have no COI related to this post.

******************************

A big thanks to Ground Truths subscribers from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you’re not a subscriber, please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support a record number of 61 summer interns here with us now! These are high school, college and medical students selected from thousands of applicants. We couldn’t do this expanded program without the funds coming in through Ground Truths.

And thank you Harshi Peiris, Ph.D., DOCTOR KLOVER 🍀, William Joseph Turner, Barry R. Davis, Robert Taylor, and hundreds of others for tuning into my live video with Sarah Urbut, MD PhD! Join me for my next live video or newsletter in the app.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Patrick Hsu: How Is AI Catalyzing Life Science?20 juil. 202600:58:12

“The future of biology is programmable.”

To give you a sense of how important this topic is, Patrick Hsu is the first guest we’ve had back to Ground Truths since the podcast began a few years ago. Nearly 2 years ago we spoke about digital biology but so much has happened since to help unravel the complexities in the language of life.

Patrick is a co-founder and core investigator at the Arc Institute. His work is at the intersection of biology, engineering, and AI. At the ripe old age of 33, he’s a pioneer of genome editing technologies and my go-to for tracking progress in digital biology. Besides that he’s a great explainer with frequent use of metaphors and simplification of very complicated stuff.

Here’s what we discussed with the relevant links:

—Our recent review in Nature Biotechnology on the large language of life models (LLLMs). GBAI-generalist biological artificial intelligence

—The 2 multi-agent AI Nature papers in May for accelerating drug discovery: Full House (Robin) and Google Deep Mind (Co-Scientist) Multiple drug candidates were described as an outgrowth of multi-agent AI , with a 200-fold decrease in workflow time.

Below Figure from synthesis of the Robin and Co-Scientist papers: “AI devises hypotheses and ways to test them,” Nature News and Views, by Oliver Elemento

—Biomni published in Science 9 July

An infographic by NotebookLM below helps give you a sense of what—a diversity of important tasks— accomplished by Biomni

—New workbench offerings by the AI companies including Anthropic’s Claude Science, Open AI, Google DeepMind and the competition with academic spinoffs

—Spud Cells

—Virtual Cell project, which it’s such a big deal, and the importance of perturbations

—Alzheimer’s disease with OpenAI for finding mechanistic new targets for drug discovery

—The Nature Editorial

—Mid-Journey’s Ultrasound Imaging of the “Whole-Body” (and we’re not imaginative enough, the need to think big)

—Mitigating the worries about humans as lab assistants and nefarious use to produce bioweapons

*******************************************************************************

A big thanks to Ground Truths subscribers from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you’re not a subscriber, please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support a record number of 61 summer interns here with us now! These are high school, college and medical students selected from thousands of applicants. We couldn’t do this expanded program without the funds coming in through Ground Truths.

Finally, thank you Alan Heldman MD, Bob Fleischman, Jeanie, Maureen Susannah, Mary Powers, and more than 400 others for tuning into my live video with Patrick Hsu! Join me for my next live video in the app.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Aaron Newman: A Breakthrough Blood Test for Cancer03 juil. 202600:47:36

The tumor microenvironment (TME), composed of immune cells, fibroblasts, and endothelial cells, has emerged as critical to pathogenesis, prognosis and treatment for cancer (schematic Figure below). There’s no such thing as TMI (too much information) for TME! Yet there’s still no way of assessing it in the clinic by a blood test, and even by invasive biopsy the sampling bias for TME without broader geographic context can lead to important mistakes. That isn’t used for clinical decision making. The TME field is about to change.

Recently, Professor Aaron Newman at Stanford and colleagues from many US leading centers published a landmark paper in Nature. It may ultimately be considered one of the most important leaps in cancer diagnostics in decades.

Ground Truths is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

This was a massive undertaking involving 10 million single-cell RNAseq in 10 types of cancer to define 9 TME types by spatial omics which they called “spatial ecotypes”. It was AI-enabled by machine learning (Spatial Ecotyper from biopsy samples) and extrapolating that to knowledge to deep learning AI (Liquid Ecotyper from blood samples). The whole project took several years.

Here’s an infographic summary I made with the help of NotebookLM along with the Figures that follow.

Some of the key points from our conversation:

—TME is the soil in which the cancer cells live. It strongly influences whether the cancer cells will thrive or not, spread, respond to therapy, and determine the fate pf pre-cancerous lesion (as seen in recent important paper in pancreatic cancer evolution and colon cancer development).

—Ecotypes, a term coined in 1922, to get at the local environment of tissue and cancer, was repurposed in this new project. Good metaphor: neighborhoods. And emphasis on location , location, location like real estate.

—In the clinic today, the only window to TME is via a biopsy. But decisions for treatment are not based on TME, they are based on biomarkers like tumor mutation burden (TMB), PD-L1 levels , or volume of tumor DNA by liquid biopsy.

—TME is dynamic and changes over time so a single snapshot won’t cut it.

—Spatial 3D maps of TME from 10 million cells, 10 cancer types led to 9 spatial ecotypes (with the Spatial Ecotyper machine learning). Validation across 3D grids (such as Visium) and multiple cohorts. The cell location base within TME is striking.

—These 9 neighborhoods are conserved and very different. SE4-immune system is asleep, hypoxic; SE 7/8 are “war zones” rich with immune cells, hot tumor; SE 5 exhibits intense immunosuppression, hostile vs immune system, portends poor survival, SE9 deep in core, driving angiogenesis (new blood vessels)

—Now rich information from these 9 SEs needs to be extrapolated to a holistic blood test of TME. It turns out an extension of tapping into methylation as used by some liquid biopsy cell-free DNA tests works very well, providing cell identity from the DNA fragments leaked into the blood. To get to TME spatial biology in a tube of blood. Akin to wastewater surveillance form municipals for detection of infectious disease pathogen sequence variants and circulating levels. A triumph of AI analytics made this possible!

—The Liquid Ecotyper was validated in 78 patients with malignant melanoma pre-treatment from Yale University. SE 7/8 benefited from immune checkpoint therapy; SE4 resisted treatment, shorter survival. Matched with tissue biopsy work.

—Work beyond publication ongoing in many types of lung cancer, bladder cancer, mesothelioma, and response to other therapies like CAR T and bispecific antibodies. This is critical since we have slew of different cancer immunotherapies (see my pyramid Ground Truths review) and we’re not sure who, when, how to use them to drive optimal cancer outcomes in patients. May also help predict other types of therapy (not just immunotherapy) for cancer.

—The blood test can performed serially which is a major advance compared with how we are currently “flying blind” and misled by imaging.

—Started a company Liquid Cell Dx to make the TME blood test commercially available. May be available sooner in the academic centers in the current study.

—The use of SEs may extend beyond cancer!

A big thanks to Ground Truths subscribers from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you’re not a subscriber, please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support a record number of 51 summer interns coming in 2026! These are high school, college and medical students selected from thousands of applicants. We couldn’t do this expanded program without the funds coming in through Ground Truths.

Thank you Dr Poonam Desai, Harshi Peiris, Ph.D., YOUR DOCTOR KLOVER, KL, Jessica Coffman, and >400 others for tuning into my live video with Aaron Newman! Join me for my next live video in the app.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Elisa Port: Discuss THE BREAST ADVICE Book26 juin 202601:03:48

“I may be the expert in cancer, but you are the expert in you.”—Elisa Port, MD

Ground Truths is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Dr. Elisa Port is Professor of Surgery, Icahn School of Medicine at Mount Sinai; Chief of Breast Surgery for the Mount Sinai Health System; Director of the Dubin Breast Center; and Director of the Center of Excellence for Breast Cancer at the Mount Sinai Tisch Cancer Center, a NCI-Designated Comprehensive Cancer Center. She is remarkably well qualified to provide guidance for prevention and treatment of breast cancer, and runs a model program at Mount Sinai in New York (←we’ll get into why I say that).

She has just published a terrific book that centers around the concept of informed optimism. Many of her patient stories are integrated.

We tried to cover the waterfront during our conversation including:

—4 Ws for reduction of risk: weight, walking, wine, and working out (especially in Nature, “green exercise”)

—Only 10-12% of women will ever develop breast cancer during their lives

—Role of adipocytes (fat cells), aka estrogen and inflammation factories

—Misinformation (underlying the need for this book)

—Pervasive myths of magic supplements, with safety issues of unregulated intravenous drips and others when analyzed turned out to be crushed up, dried house plants

—Total body MRI: mixed results from her patients

—Breast cancer on the rise in young women. Dr. Port relates about recent patients diagnosed in their 20s. Some without BRCA or other pathogenic mutation. Why?

—Mammograms in non-dense breasts pick up 80-90% of breast cancer. It’s the 40-50% women with dense breasts, which the scan is trying to find a polar bear in a snowstorm, is a problem. The problem with false-positives.

—Use of AI with mammography for increased initial detection, prevention, detect high-risk in women with a “normal” mammogram, and risk of heart disease (see my recent Ground Truths and piece in The Lancet on this important topic)

—Mount Sinai provides Transpara AI (the one validated by the big Sweden trial of >100,000 women) to all women getting mammograms FOR FREE. That is the best validated AI tool in medicine today!

—How a mammogram saved a patient’s life, not about breast cancer!

—Hormone replacement and birth control pills. How to assess benefit and risk in women young and older? Differences in the hormone risks.

—Tamoxifen for primary prevention in high-risk people. Reduction of breast cancer in 50% or more in these women. In some subgroups reduction as high as 80%!

—GLP-1 drugs may reduce breast cancer risk and this may not just be related to weight loss

—Lack of utilization of Genetic testing (it could be your father). I disagreed with respect to use of polygenic risk scores, as I wrote about in SUPER AGERS

—“I just wanted to scream out on top of the mountain about genetic testing, family history, and early screening.” Tennis legend Chris Evert

—The lack of our ability to assess the immune system in the clinic and how that could change the face of prevention and very early detection of breast cancer

An infographic summary I made on Dr. Port’s book with the help of NotebookLM

****************************************

Thank you YOUR DOCTOR KLOVER, Diane Romero, Bob Fleischman, Danielle, MagnaAnimus, and 450+ others for tuning into my live video with Elisa Port! Join me for my next live video in the app.

A big thanks to all the Ground Truths subscribers from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you’re not a subscriber, please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support a record number of 51 summer interns coming in 2026! These are high school, college and medical students selected from thousands of applicants. We couldn’t do this expanded program without the funds coming in through Ground Truths.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Helen Pearson: What Constitutes Real Medical Evidence?06 juin 202600:51:45

Helen Pearson, PhD, is an award-winning biomedical journalist at Nature, named European Science Journalist of the Year in 2025. She teaches science writing at University College London. BEYOND BELIEF is her second, just published book. THE LIFE PROJECT was her first.

The points we covered include:

—The evolution of evidence over 8 decades, moving from rationalism, expert opinion, hunches (eminence-based) to empiricism, evidence-based

—The enormous devastating adverse impact of Dr. Spock’s Baby and Child Care book from a single sentence change, leading to an epidemic of sudden infant death syndrome. And how it ultimately got corrected.

—The term evidence-based medicine was coined in 1991 at McMaster University

—Iain Chalmers, Archie Cochrane and the Cochrane Collaboration

“The scandalous failure of science to cumulate evidence scientifically”—Iain Chalmers

—Systematic reviews

—Natural experiments (such as with Shingles)

—Resistance to change

“Challenging a doctor’s conventional way of practice is like hitting him in the intellectual testicles”—Drummond Rennie, past JAMA editor

—Evidence-based practice (and not) in the Covid pandemic

—Recent examples of challenging dogma (kindly stones, thymus involution)

—AI and misinformation, false evidence

Thank you Harshi Peiris, Ph.D., Ageless Mind Project, Anthony Higgins, E West, MagnaAnimus, and many others for tuning into my live video with Helen Pearson! Join me for my next live video in the app.

A big thanks to Ground Truths subscribers from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you’re not a subscriber, please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support a record number of 51 summer interns coming in 2026! These are high school, college and medical students selected from thousands of applicants. We couldn’t do this expanded program without the funds coming in throughGround Truths.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Assessment of the Hantavirus with Prof Donald Milton14 mai 202600:52:02


Get full access to Ground Truths at erictopol.substack.com/subscribe
Joanna Stern: An AI Immersion for 365 Days13 mai 202600:58:08

Joanna Stern was the Wall Street Journal technology journalist for 12 years. She’s an Emmy award winner for her documentary E-Ternal, and recently started her own company New Things, with added advice from ChatGPT!

Over the years at WSJ, I relied on Joanna’s reviews of technology for many purchases (and things I avoided) reflecting her keen and brutal assessments. I also had fun working with her on some of her video assessments of health technologies.

Her book I AM NOT A ROBOT is both hilarious and highly informative. It is a terrific primer for those who are not fully grounded in AI getting into the history of AI and right up to date with generative AI’s progress.

To get a sense for why AI thought she was the next Tina Fey, check out the back cover! No surprise she got me laughing hard throughout the conversation, no less while reading the book.

Here is a short YouTube video she posted on her All In AI year of 2025, referred to during the podcast.

Much of her testing of >100 AI products related to medicine and health care, which is what we especially got into during our conversation. She has 3 major rules in her assessment of AI: (1) Ruthless testing; (2) Benchmark vs human; and (3) Costs, which include “compute cost” that we discussed.

Here are some of the things we covered:

* AI of her blood work

* AI of mammogram and breast ultrasound, and overall experience as a person with increased risk of breast cancer

* AI at the dentist (and ”Dentist Deep Clean”)

* Assessment of Dr. GPT

* Bill Gates on health AI

* Her AI Trainer (Chris)

* Waymo vs Uber

* Her AI Therapist (Ash)

* Nothing Bot Sex (her 2 digital lovers)

* Impact on her children (including 6 F*****g Hamsters, the robodog Sirius)

A big thanks to Ground Truths subscribers from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you’re not a subscriber, please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support a record number of 51 summer interns coming in 2026! These are high school, college and medical students selected from thousands of applicants. We couldn’t do this expanded program without the funds coming in through Ground Truths.

Thank you Tara Parker-Pope, MPH, Tracy Paeschke, MD, FACC, Chip Hughes, Bob Fleischman, Gretchen Faucett, and >400 others for tuning into my live video with Joanna Stern! Join me for my next live video in the app.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Roxanne Khamsi: We Are All Genetic Mosaics25 avr. 202600:51:36

“You are a slightly different genetic version of yourself today from yesterday, and will be different yet again tomorrow.”—Roxanne Khamsi

“Each neuron really is a beautiful and unique snowflake”—Ed Yong

Roxanne Khamsi is one of the leading life science journalists, a contributing writer at The Atlantic, recognized with multiple awards for notable publications. Her new book is entitled BEYOND INHERITANCE. It tells the story about us all being genetic mosaics, chock full of somatic (acquired) mutations, and the implications of those mutations for our health. The myth of a single genome, carbon copy, master blueprint, but instead a dynamic, shifting mosaic in constant internal evolution.

And here’s the back cover. I was delighted to endorse this book, and reread it to prepare for our podcast. It’s extraordinary and mind-bending.

Here are the topics we covered:

—The Math. 330 billion cells of our ~37 trillion turnover each day, which yields trillions of mutations per day.

—Cellular competition. Winners and losers of an “endoevolution,” Darwinian selection inside us whereby healthy or super-fit mutated cells can crowd out the unfit ones.

This was theorized in 1881 in a book THE STRUGGLE OF PARTS, by Wilhelm Roux

which led to Friedrich Nietzsche’s famous quote “Uniformity is pure delirium.”

—Single-cell sequencing. How this field catapulted forward owing to the ability to zoom in on genomic mutations at the cellular level.

—Cancer chemotherapy overkill. The routine scorched earth, carpet bombing approach can promote resistance and deleterious mutations, leading to an adaptive strategy of leaving some cancer cells behind, as has been shown to be effective in prostate cancer for improving survival.

—The immune system somatic hypermutation. B cells have the theoretical capacity to produce 1 quintillion unique antibodies (a million trillion). If this weren’t possible, we could die from a common cold. In the Covid pandemic, even before the Omicron variant appeared, Covid booster shots induced hundreds of unique antibodies with neutralization capacity against Omicron. The anticipatory “Red Queen” effect.

—Autocorrection of mutations. They can revert, cure a rare genetic disease from within. It can be considered “Natural Gene Therapy.” Example below of a skin condition Epidermolysis Bullosa with revertant mutations (→ normal skin appearance)

—Different role of acquired mutations through the lifespan. Examples: At embryonic stage, Lines of Blaschko (Image below). In mid-life endometriosis, and in older adults Loss of the Y chromosome (LOY) and Clonal Hematopoiesis of Indeterminate Potential (CHIP). Note these 2 somatic mutation clone conditions are associated with risk of diseases; CHIP-cardiovascular and cancer; LOY-heart failure and Alzheimer’s. I’ve written about CHIP extensively here and here.

—Phenocopy. How a somatic mutation can look the same as a germ-line, inherited mutation, with respect to a disease, and how that is determined.

—Environmental effects inducing somatic mutations: UV light, air pollution, plastics

—and 3 new papers in the past week!

* Somatic mutations in the microglia cells of the brain, same as cancer mutations, drive inflammation and are enriched in the Alzheimer’s brain

2.. The potential of “promolytic drugs” to be used to prevent cancer in people who exhibit precancerous somatic mutations

3. How somatic mutations can be the basis of autoimmune diseases

We also spoke about the role of somatic mutations in aging and super aging

A related excerpt at The Atlantic

A Quick Poll

Thank you YOUR DOCTOR KLOVER, Stephen Pribut, Elizabeth J., Maureen Susannah, Gretchen Faucett, and more than 500 others for tuning into my live video with Roxanne Khamsi! Join me for my next live video in the app.

And a big thanks to Ground Truths subscribers (> 205,000) from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. Please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. We just accepted 51 interns for the 2026 summer, a new record, from thousands of high school, college, and med school student applicants. Our fully loaded cost to do this program is ~$300,000 per year. We’re deeply appreciative for your support of Ground Truths that has enabled this program to prosper and expand.

One more thing:

SUPER AGERS was featured on the CBS Morning Show this week in a segment with Dr. Jonathan LaPook, Chief Medical Correspondent, on the meaning and measurement of biological aging.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Sebastian Mallaby: The Infinity Machine19 avr. 202600:53:43

This is one of my favorite books over recent years. Sebastian Mallaby is the Paul A. Cocker Senior Fellow for International Economics at the Council of Foreign Relations and author of 6 bestselling books.

THE INFINITY MACHINE tells the story of AI’s progress over the past 15 years largely, but not exclusively, from Demis Hassabis as the protagonist and leader of DeepMind’, with its 2010 mission statement to achieve superintelligence by 2030. It’s a rich, informative, page turner.

What We Discussed:

—What is an Infinity Machine?

—Influence of Claude Shannon’s Information Theory and Douglas Hofstadter’s Pulitzer Prize winning book Gödel, Escher, Bach

—Origin of DeepMind in 2010. Prescient. Charter, business plan, included use of agents. How Demis Hassabis was made for the mission!

—Contrasts with Sam Altman and the other AI leaders, the Oligopoly (cover of The Economist this week). For example, Nature papers vs white papers on company websites.

—In March 2016, the same day when DeepMind’s AlphaGo beat Lee Sedol, Hassabis says it’s time to do protein folding (later known as AlphaFold).

—Symbolic AI (historic, deductive, rule-based) vs Deep Learning (Toronto tribe) and Reinforcement Learning (Alberta tribe).

—The Big Miss: DeepMind’s lack of early recognition of the importance of transformer models (leading to ChatGPT), creating a big opening for OpenAI. And why was this missed? The Comeback Story. Is this happening again with coding (not in the book)?

—The AI Arms Race and Hyperscaling

—How the complex relationship between Google and DeepMind evolved

—The Double Cross

—With the dangers anticipated (parallels to Oppenheimer, Manhattan Project, and the atomic bomb), how to promote AI safety?

—Is the major build up of data centers justified?

Thank you Bob Fleischman, Jeanie, Ruben Max, FelonBroke America, Seitzinator ❌👑, and more than 600 others for tuning into our live video with Sebastian Mallaby! Join me for my next live video in the app.

And a big thanks to Ground Truths subscribers (> 200,000) from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. Please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support 47 summer interns in 2025! We aim to accept even more of the several thousand who will apply for summer 2026.

And, if you’re interested on extending healthspan, two recent podcasts/TV segments on SUPER AGERS

On With Kara Swisher

On PBS



Get full access to Ground Truths at erictopol.substack.com/subscribe
Trisha Pasricha: How to Get to Poophoria, Making Your Bowel Movements a Joy!10 avr. 202600:56:49

Dr. Trisha Pasricha is a gastroenterologist, Assistant Professor at Harvard Medical School, and the Ask a Doctor columnist for The Washington Post. Her new book gets deep into the stigmatized, taboo, rarely discussed topics of our bowel movements and farts, no less the science that backs that up, with lucid explainers for the mechanisms (such as the gut-brain axis). Her research is on the gut origin of Parkinson’s disease.

Here’s a quote from Trisha early in the book:

“I’m not a wellness guru. I’m a scientist.”

Another quote from a Vanderbilt professor:

“An effortless, socially appropriately timed bowel movement is the second greatest bodily pleasure known to man.”

The proportion of people with bowel issues is remarkable, a brief summary:

Some of the topics covered in our lively, fun and highly informative conversation:

—The 3 P’s Propulsion, Pliability, Pelvic Floor

—Ten Myths

—99% of farts have no odor; the 1% that do are from hydrogen sulfide, Pepto-Bismol substantially reduces the latter (and an incredible experiment of people with rectal tubes and judges smelling their gas)

—What is the normal frequency of pooping?

—the Bristol Scale of poop appearance and what it means

—Transit time

—The uselessness and danger of bowel cleanses

—Fibermaxxing

—5 minutes max on the toilet and positions to help propulsion

—Psyllium and laxatives

—The art of wiping and bidets

—Fecal incontinence

—Not to miss urges and the TRPV1 and PIEZO2 receptors

—Impact of coffee, alcohol, NSAIDs (Ibuprofen, aspirin, naproxen, etc), and hydration

—What are the different definitions of constipation?

—What gives poop its color?

********************************************

Thank you YOUR DOCTOR KLOVER, Nickhil Jakatdar, Ph.D., Bob Fleischman, karemm, Jessica Nguyen, and >600 others for tuning into our live video with Trisha Pasricha! Join me for my next live video and newsletters in the app.

And a big thanks to Ground Truths subscribers (> 200,000) from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. Please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support 47 summer interns in 2025! We aim to accept even more of the several thousand who will apply for summer 2026.



Get full access to Ground Truths at erictopol.substack.com/subscribe
On the Future of Species29 mars 202600:45:21

Adrian is a molecular biologist and co-founder and CEO of Genyro, a synthetic biology company. He has published 2 previous books on life science (Life Without Genes and An Intelligent Person’s Guide to Genetics). In this conversation we discussed his new book, cover below and the title of this post.

ABI. As Adrian puts it, a monumental shift, a second genesis, the “artivolution,” ability to use a molecular Gutenberg press, it’s post-Darwinian.

I made an infographic about the book and our conversation with NotebookLM

The expansion of genome sequences beyond “Fred’s library” (referring to Fred Sanger, father of genome sequencing, little green box)

We talked about the jump from DNA reading to editing and now writing genomes, with the potential of the latter for both good and harm. I disagreed with Adrian about the bright prospects for curing diseases, but there are many possibilities for positive impact, such as intervening vs the climate crisis and sustainability.

We also discussed the large language of life models (LLLMs) and by coincidence my colleagues and I just published a review of these in this Nature Biotechnology (←free access is hyperlinked).

“It should be possible to meet most of humanity’s needs through biologically inspired designs—to solve many global problems, revolutionize health care, extend human lifespan, and create other organisms to order.”—Adrian Woolfson

If you are into life science, I think you’ll find Adrian’s book thoughtful and provocative, even if you don’t agree with some of his optimism like a disease-free organism.

The topic connects with digital biology, a theme that is approached in many editions of Ground Truths, such as this one with Patrick Hsu

***************************************************

Thank you Ric Bayly, Kevin Johnson, MD, YOUR DOCTOR KLOVER, Patricia Scott, Anne, and more than 600 others for tuning into my live video with Adrian Woolfson! Join me for my next live video in the app.

And a big thanks to Ground Truths subscribers (> 200,000) from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. Please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support 47 summer interns in 2025! We aim to accept even more of the several thousand who will apply for summer 2026.



Get full access to Ground Truths at erictopol.substack.com/subscribe
A Master Class on Sleep 06 mars 202600:57:10

Yo-El Ju is the Barbara Burton and Reuben Morris Professor of Neurology at Washington University, St. Louis. She got her AB from Harvard and MD from Columbia and actively practices sleep medicine and is a prolific researcher, one of the top sleep scientists in the country.

Here are some of the topics we discussed and a few related hyperlinked citations:

—Importance of Deep Sleep (and her paper on what happens when deep sleep is purposely disrupted, how it is modulated, effect of alcohol

—The Orexin Antagonist drugs that promote sleep (and a study that shows they can reduce p-tau217 and other neuroinflammation markers

—Link of sleep regularity with less all-cause, cardiovascular, and cancer related mortality

Figure 3.9 from SUPER AGERS (SRI-sleep regularity index)

More things we discussed:

—A sleep foundation model that predicts 130 diseases

—Impact of menopause on sleep

—Getting to sleep vs staying asleep

—Role of naps

—Impact of interruptions of sleep

—Sleep apnea and new interventions

—Vagal nerve stimulation and sleep

—Cerebrospinal fluid wave that occurs during attention lapse after poor sleep

—cognitive behavioral therapy for improved sleep

—Wearables, sleep scores, and effect on sleep

—Any supplements that help sleep?

—The rare genetically endowed short sleepers

Thank you Jeoffry Gordon, MD, MPH, Dr. Sara Wolfson, Lynn L, Vau Geha, Bernie Newman, and more than 600 others for tuning into my live video with Yo-El Ju! Join me for my next live video in the app.

**************************************************

Thanks to Ground Truths subscribers (> 200,000) from every US state and 210 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. Please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support 47 summer interns in 2025! We aim to accept even more of the several thousand who will apply for summer 2026.

+++++++++++++++++++++++++++++

I also want to thank the National Academies of Science, Medicine and Engineering for their recent recognition.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Robert Wachter & Eric Topol - Discuss a Giant Leap Book04 févr. 202600:45:47


Get full access to Ground Truths at erictopol.substack.com/subscribe
Vagus Nerve Stimulation and the Immune System01 févr. 202601:03:59

The vagus nerve, also known as the Great Nerve, connects the brain to all parts of the body, like an internet (Figure below). Every week we’re learning more about its importance for health and disease. Until recent years the brain and immune system were thought to be in separate “firewalled” compartments. But that turned out to be far from the truth.

Dr. Kevin Tracey, who directs the Feinstein Institute at Northwell Health, has been studying the vagus nerve for more than 3 decades. In the early 1990’s he made the seminal observation that stimulating the vagus reduces the inflammatory cytokine known as tumor necrosis factor (TNF), what he described at the time as a “holy s**t” moment. In 2025 he published the book THE GREAT NERVE with many rich patient anecdotes and the history for how this field developed.

I wrote about the brain-immune axis previously on Ground Truths, spotlighting the vagus nerve’s role. That included much more on depth of the pathways if you are interested.

We discussed the recent FDA July approval for refractory rheumatoid arthritis (RA)(unresponsive to medications or intolerance to medical therapy) based on a sham-controlled randomized trial published in December 2025 in Nature Medicine. It is striking that the benefits were derived from 1 minute of vagal stimulation per day. That stimulation is barely perceived (tingling, many not at all) by device recipients. The surgery takes one hour to implant the tiny stimulator device along side the vagus nerve in the neck.

But this is much bigger than a treatment for RA. It is now being tested for lupus, Crohn’s disease, and other autoimmune conditions. That’s beyond the role vagus nerve stimulation (VNS) has played for epilepsy and depression, independent of VNS’s anti-inflammatory impact (Tracey named it “the inflammatory reflex”).

We also discussed handheld VNS devices, potential use for Long Covid and POTS, cold plunges, heart rate variability, stress, and other topics related to the vagus nerve and parasympathetic nervous system (the brakes, “rest and digest” as opposed to the sympathetic nervous system (the gas, “fight or flight”).

Most people are not aware of this device approved treatment for an autoimmune disease. Our treatments are so drug-centric but they are immunosuppressive, have important side-effects, and are expensive. It’s good to see a non-drug approach get compelling data as an alternative. Moreover, as I recently wrote about, there’s a shift ongoing from treatment to cures vs autoimmune diseases that will be adding to the mix.

Here are some very recent papers about the vagus nerve to give you a sense about how its prominence is getting appreciated more all the time

Gut-brain-vagus axis for reward circuit and addiction, 30 Jan 2026, Science Advances

Randomized trial of VNS for depression , Int J of Neuropsychopharm 2026

The vagus nerve role in heart function after a heart attack, Cell, February 2026

Vagus receptors and hemorrhage, blood volume, Nature, 28 Jan 2026

A Quick Poll

Thank you Harshi Peiris, Ph.D., Tay MacIntyre, David Dansereau, MSPT, Max Manwaring-Mueller, RJ, and over 600 others for tuning into my live video with Kevin J. Tracey, MD! Join me for my next live video with Robert Wachter Feb 4th, 12:30 PM PT in the app.

**********************************************

Thanks to Ground Truths subscribers (approaching 200,000) from every US state and 210 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. Please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support 47 summer interns in 2025! We aim to accept even more of the several thousand who will apply for summer 2026.



Get full access to Ground Truths at erictopol.substack.com/subscribe
A Look Into the Blue Zones18 janv. 202600:55:31

Back in 2005 Dan Buettner patented Blue Zones. He’s written 9 books, of which 5 were NY Times bestsellers, and has another one in the works. His 2023 Netflix documentary series “Live to 100: Secrets of the Blue Zones” won Emmy awards and was widely viewed. Many of the main points that Dan has emphasized over the years—healthy diet (he highlighted whole grains, beans, nuts, greens, and “peasant food” here), physical activity, social engagement, and sense of purpose—are backed up by randomized trials and/or large, prospective studies, as I reviewed in Super Agers.

In this interview, I asked Dan about the critique he’s faced, predominantly from Saul Newman, a biologist in the UK, about accuracy of the data for extreme longevity in the blue zones. In December 2025, two of his collaborators published in The Gerontologist a rebuttal response (open-access) entitled “The validity of Blue Zones demography: a response to critiques” on the rigorous demographic work they’ve done.

We also discussed the marketing and business operations of Blue Zones LLC, the company he sold to Adventist Health in 2020. His son, Danny, is the EVP of the company and likely successor to Dan’s work in the future. As Dan said, “He’s my genetic upgrade.”

I hope you find this conversation informative. An AI-generated transcript is available in the tab at top right above.

Some biomedical updates from the past week:

* A vaccine to prevent colon cancer in carriers of mutations of Lynch Syndrome looks good for strong immune response and safety, ready for Phase 3 clinical trials

* A review of the data of Tylenol during pregnancy reaffirms its safety and lack of increased risk for autism, ADHD, and intellectual disability.

* Our perspective/review on how AI and large language models can reduce global health inequities

* Another big jump vs refractory autoimmune diseases, this time for hemolytic anemia, using engineered T cells. See my recent review of this topic, from treatment to cures.

* A pair of new large prospective cohort studies that reinforce the importance of even small increases in physical activity, along with sleep and diet, for reduction all-cause mortality and improvement in healthspan.

Thanks to Ground Truths subscribers (nearly 200,000) from every US state and 210 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. Please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support 47 summer interns in 2025! We aim to accept even more of the several thousand who will apply for summer 2026

Thank you Annie Fenn, MD, Harshi Peiris, Ph.D., Strategy Shots, Rebecca Moore, Lynn L, and many others for tuning into my live video with Dan Buettner! Join me for my next live video in the app.



Get full access to Ground Truths at erictopol.substack.com/subscribe
How Our Brain Drains Its Waste Products21 déc. 202500:56:21

Jonathan Kipnis is a neuroscientist, the Alan A. and Edith L. Wolff Distinguished Professor of Pathology and Immunology at Washington University, St. Louis, who discovered meningeal lymphatics and has been a prolific researcher in brain drainage and the continuous immune system surveillance of the brain.

I made this infographic with the help of Notebook LM to summarize many of the concepts we discussed. (Notebook LM is free and worth trying)

We went over his new review with 24 co-author leading experts in the recent issue of Neuron

A Clever Cover

The drainage system anatomy on influx and efflux (blue arrows)

The 3 ways the flow of glymphatics are modulated. I mentioned the recent studies that show atrial fibrillation, via reduced cardiac pulsation, has an effect on reducing glymphatic flow.

We also discussed his recent review on the immune surveillance system in Cell:

A schematic of key channels for the “faucet” and “drain”

and how the system changes from healthy to central nervous system autoimmune diseases (such as multiple sclerosis) and aging with different immune bar codes.

The outsized role of astrocytes in the brain, a subject of recent Nature feature, was also mentioned.

Our understanding of the brain’s immune system has been completely revamped. Kipnis’s recent review in Nature Immunology highlights the critical role of the outer layers —the skull, dura and meninges—as an immune reservoir that is ready to detect and react abnormalities in the brain with a continuous “intelligence report.”

Notably, Kipnis touched on lymphatic-venous anastomosis (LVA) surgery (Figure below) for Alzheimer’s disease which is popular in China, available at 30 centers in multiple cities, and the subject of multiple randomized trials as a treatment for Alzheimer’s. Trials of LVA surgery are also getting started in the United States for treatment of Alzheimer’s and Parkinson’s diseases.

Here is a Figure to show the surgical anastomoses (connections) from the deep cervical lymphatics to external jugular and internal jugular veins

This podcast was packed with insights relevant to health, spanning sleep quality, sleep medications, autoimmune diseases, and Alzheimer’s disease. I hope you find it as informative and engaging as I did.

A Poll

************************************

This is my 4-year anniversary of writing Ground Truths. Post number 250! That’s an average of more than 1 per week, nearly 5 per month. Hard for me to believe.

Thanks to Ground Truths subscribers (approaching 200,000) from every US state and 210 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. Please join!

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support 47 summer interns in 2025! We aim to accept even more of the several thousand who will apply for summer 2026

Thank you EG, Alan, Lynn L, Stacy Mattison, Jackie, and many others for tuning into my live video with Jonathan Kipnis! Join me for my next live video in the app.



Get full access to Ground Truths at erictopol.substack.com/subscribe
The Story of Francis Crick, a new masterpiece biography by Matthew Cobb07 déc. 202500:59:14

A recording from my enthralling conversation with Prof Matthew Cobb about the life and science contributions of Francis Crick, regarded as one of the most influential biologists of all times, along with Darwin and Mendel. As you’ll see, there’s so much more to Crick’s story than cracking DNA’s double helix structure in a matter of weeks with James Watson. Matthew Cobb, Emeritus Professor of the University of Manchester, has written several award-winning books on life science, but I think this is his most important one to date, deeply researched and a thrilling account of Crick’s life, clearing up, as best as one can, many questions, and presenting some surprises.

The transcript is available (A.I. generated) by clicking at the top right.

A few things we discussed

—Crick’s reaction to James Watson’s book

Crick contrasted his own approach to science writing with Watson’s memoir: “The difference between my lecture and your book is that my lecture had a lot more intellectual content and nothing like so much gossip. (...) Your book on the other hand, is mainly gossip and I think it a pity in this way that there is so much of it that it obscures some of the important conclusions which can be drawn of what we did at the time”.

—The Peyote Poem, by Michael McClure (part 1) that had a big influence on Crick

—Crick’s 1994 neuroscience book “The Astonishing Hypothesis”

“You, your joys and your sorrows, your memories and your ambitions, your sense of personal identity and free Weill, are in fact no more than the behavior of a vast assembly of nerve cells and their associated molecules.”—Crick

The book has been reviewed at Science, Nature, The Economist and many other journals. Here is a gift link to The Economist It has deservedly been named a best book of 2025 by The Guardian, The Economist, and many other media.

Thank you Bruce Lanphear, Harshi Peiris, Ph.D., Elisabetta Pilotti, Allan Konopka, Stephen B. Thomas, PhD, and over 500 others for tuning into my live video with Matthew Cobb!

*********************

Upcoming, this Wednesday 9AM PT, live podcast

I will be interviewing Dan Buettner founder of the Blue Zones

Join us!

**********************

Thanks to US News for recently being named one of the 25 best leaders in the United States

https://www.usnews.com/news/leaders/articles/best-leaders-2025-eric-topol

^^^^^^^^^^^^^^^^^^^^^^

Thanks to >190,000 Ground Truths subscribers from every US state and 210 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile.

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support 47 summer interns in 2025! We aim to accept even more of the several thousand who will apply for summer 2026.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Jennifer Gunter & Eric Topol: Discuss Women’s Health and Recent Changes by FDA for MHT28 nov. 202501:00:50

A couple of weeks ago, the FDA Commissioner published a WSJ oped “The FDA Liberates Women’s Hormone Replacement Therapy” (←gift link) and, with other FDA colleagues, a JAMA essay entitled “Updated Labeling for Menopausal Hormone Therapy” (open-access). That change, and the data cited, led to a series of articles in the days that followed, such as at STAT News “FDA reverses decades-old warning on hormone therapy products for menopause. Agency says the treatments o!fer heart, brain, and bone health benefits” and at the Washington Post “The FDA finally corrects its error on menopause hormone therapy. Women have been needlessly scared away from effective treatments.” If you read through these links, you’ll be confused. Does MHT have proven cognitive benefits? What about a study from 1991 that showed ~50% reduction of fatal heart events with MHT? Or the 35% decreased risk of Alzheimer’s disease? Or the breast cancer increased risk attributed to medroxyprogesterone acetate?

I turned to my go-to gynecologist truth teller, Dr. Jen Gunter, to get her review of the evidence. This is a complex topic, with old data from the 2002 Women’s Heath Initiative (WHI), new reports since, population level analysis, changes in preparations of MHT including local delivery, and much more.

Here is our conversation which isn’t just about MHT but includes “Big Wellness” marketing direct to middle aged women, the new FDA approved drug for hot flashes, the $14 million cut of the NIH’s Office of Women’s Health , marked increase in philanthropic support of women’s health research, the Surgeon General nominee, ovarian failure, and a lightning round on proven benefits of MHT.

Here’s a brief clip on her views of the women’s health “wellness” predators

We also discussed the reasons for Dr. Gunter’s planned move next year back to Canada after practicing gynecology for 3 decades in the United States.

I referred to a recent GT I wrote about the WHI and the potential favorable impact of MHT on the immune system, as suggested by new data on organ clocks. That finding, which has been replicated, may be linked to healthy aging, extending healthspan.

****************************

Thanks to the >190,000 Ground Truths subscribers from every US state and 210 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile.

If you found this interesting PLEASE share it!

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don’t hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support 47 summer interns in 2025! We aim to accept even more of the several thousand who will apply for summer 2026.Thank you Debbie Weil, Cynthia Brumfield, Sara Garcia, Harshi Peiris, Ph.D., Liane Moccia, and over 1,000 others for tuning into my live video with Dr. Jen Gunter! Join me for my next live video in the app.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Dr. Susan Monarez—Former CDC Director, First Live Interview08 nov. 202500:54:36

Dr. Susan Monarez was the first CDC Director to be confirmed by the Senate and served from July 31, 2025 – August 27, 2025. Because she refused to give approval to new vaccine recommendations without ever seeing them or their evidence and firing scientists without cause, she was fired. In my view, she’s a hero for standing up for science and speaking truth to power.

In her first live interview since leaving the CDC, we review her background. That includes growing up in rural Wisconsin and getting her college and PhD education at UW-Madison, the latter in microbiology and immunology. She then went on to 18 years of government service with an extensive portfolio of jobs and management at BARDA, the White House, ARPA-H, and others, before becoming Acting Director of the CDC in early 2025.

We discussed the horrific CDC shooting on August 8th, days after she started. Then we reviewed a conversation that we had on August 19th in which she laid out her exciting vision for the future of CDC, emphasizing the goal of prevention (BTW, CDC stands for Centers for Disease Control and Prevention) and asked me to help as an advisor. At the time, she was well aware, with growing tension, that her tenure at CDC might be limited.

I asked about her perspective for the jobs of 4,300 people at CDC who have been terminated, which account for more than 1/3rd of the workforce, no less the gutting of the budget.

Then we got into what she learned from this ordeal and her plans for the future, which includes a very ambitious initiative: 90/90/2035. As you’ll see from our conversation, Dr. Monarez is exceptionally resilient and an optimist. She’s got lots to do in the years ahead to carry out her mission of promoting human health!

Dr. Monarez just started a Substack The Road Best Traveled so you can follow her there. It was a real privilege for me to do this interview with her. In deep admiration of her willingness to not only take on the job of CDC Director in tough circumstances, her professionalism during testimony at the Senate committee hearing, her impressive yet unrealized vision for transforming the CDC, and refusing to cave to immense pressure from the HHS Secretary to move ahead with his agenda.

Thank you Julie, Stephen B. Thomas, PhD, David Dansereau, MSPT, Dr. Sara Wolfson, Vau Geha, and >500 others for tuning into my live video with The Road Best Traveled!

Thanks for being a Ground Truths subscriber! Please spread the word.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Seth Berkley & Eric Topol - Discuss Fair Doses Book05 nov. 202500:47:19


Get full access to Ground Truths at erictopol.substack.com/subscribe
Tom Frieden & Eric Topol - Discuss the Formula for Better Health Book01 oct. 202500:35:02


Get full access to Ground Truths at erictopol.substack.com/subscribe
Shana Kelley: Biosensors to Track Proteins and Inflammation in Our Blood in Real Time14 sept. 202500:31:17

Prof Shana Kelley is the Neena Schwartz Professor of Chemistry and Biomedical Engineering at Northwestern University and President of the CZI Chicago Biohub, which brings together life scientists at Northwestern, University of Chicago, and U. Illinois Urbana Champaign. Her lab’s website provides recent publications in the 3 major areas of biomolecular sensors, rare and single cell analysis, and intracellular molecular delivery.

You are undoubtedly familiar with wearable biosensors on the wrist and rings, and continuous glucose monitoring (CGM), all of which can transmit physiologic data in real time to your smartphone. What is different about Prof Kelley’s work is the ingenious way of continuously tracking any proteins in our blood via a sensor that could function just like CGM in the future (hair thin sensor applied just below the skin and data relayed to your smartphone). A proof-of-concept paper in Science showed how exquisitely sensitive such a sensor worked to track inflammation markers [interleukin-6 (IL-6) and tumor necrosis factor (TNF)] in the diabetic rat model. As seen. below, just the injection of insulin evoked inflammation, and introduction of lipopolysaccharide (LPS) did so markedly.

This capability opens up the potential for monitoring body-wide inflammation in real time, but also extends to many other conditions such as autoimmune diseases, heart failure (e.g. continuous brain natriuetic peptide monitoring), and neurodegenerative diseases (with specific markers of neuroinflammation). This innovation represents a new dimension in individualized (precision) medicine.

In our conversation, Shana takes us through the discovery of these unique bimolecular sensors that have no reagents, and use electricity to shake off the protein from DNA strands. And she maps out the path to clinical trials and commercialization in the next couple of years.

Thank you Stephen B. Thomas, PhD, Linda Kemp, Lynn L, Pat Mumby PhD, David Hobson, and many others for tuning into my live video with Shana Kelley! Join me for my next live video in the app, along with posts on biomedical news and analysis.

***********************************************************************

Thanks you for your listening, reading and subscribing to Ground Truths.

If you found this interesting PLEASE share it!

That makes the work involved in putting these together especially worthwhile.

All content on Ground Truths—its newsletters, analyses, and podcasts, are free, open-access.

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support 47 summer interns in 2025!



Get full access to Ground Truths at erictopol.substack.com/subscribe
Charlotte Blease: Is A.I. Going to Remedy Medicine’s Problems?12 sept. 202500:30:37

Thank you Bruce Lanphear, Clyde Wilson, Tracy Dennis-Tiwary, Diego Pereyra, Dr Mike Hunter, and many others for tuning into my live video with Charlotte Blease! Join me for my next live video in the app.

Whether A.I. will transform the practice of medicine in a positive way remains controversial. Health researcher Prof Charlotte Blease, on faculty at Uppsala University in Sweden and researcher at Harvard University, has written a new book —Dr. Bot—that critically assesses the unmet needs in healthcare and whether A.I. can fulfill them. She provides an optimistic viewpoint (see the subtitle), and our conversation probes whether that is justified. She has a substack, too, here

Thanks for listening to Ground Truths. Through analytic essays and podcasts, I try to cover the important issues and discoveries in life science and medicine. If you have suggestions for topics I should get into, please pass them along.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Peter Hotez & Eric Topol - Discuss “Science Under Siege” book08 sept. 202500:53:07

Thank you Sara Garcia, Andrew O'Malley BSc PhD, Sam Hester, Julie, Stephen B. Thomas, PhD, and so many others for tuning into my live video with Peter Hotez! Join me for my next live video in the app.

Peter Hotez and I discuss his new book, co-authored with Michael Mann, SCIENCE UNDER SEIGE, on the anti-science superstorm culminating from the climate crisis, the Covid pandemic, and a vast interconnected network that has waged a direct assault on scientific truth.

During our conversation we trace history of priors in civilization, such as Lysenko and Stalinism in the last century. And acknowledge the future role of A.I. for promoting infinite disinformation.

Beyond human suffering and direct health outcome consequences (such as Red Covid), the toll this is taking on the career of young scientists, universities, public health agencies, and loss of public trust are reviewed. The interdependent role of the media and the wellness industry is touched on.

The book and our conversation puts forth a call to arms, potential solutions, including the need to move away from invisible scientists and political activism.

Thanks for listening to Ground Truths podcasts and reading the analytic posts.

In case you missed any, these are a few recent and related ones:

Podcasts with Michael Osterholm and Sanjay Gupta on their new books—The Big One and It Doesn’t Have to Hurt, respectively.

Next up is Charlotte Blease and her new book Dr. Bot on where we are headed with medical A.I.

If you found this interesting PLEASE share it!

That makes the work involved in putting these together especially worthwhile.

All content on Ground Truths—its newsletters, analyses, and podcasts, are free, open-access.

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Sanjay Gupta & Eric Topol - Discuss “It Doesn’t Have to Hurt” book05 sept. 202500:22:06

Thank you Jose Bolanos MD, Dr. Zeest Khan, Lawrence Toole, Julie, Stephen B. Thomas, PhD, and many others for tuning into my live video with Dr. Sanjay Gupta. Join me for my next live video in the app.

A Brief Summary of Our Conservation

We discussed the new understanding and approach to chronic pain, which affects nearly 1 in 4 adults. Dr. Gupta gets personal telling the story of his wife, Rebecca, who has an autoimmune disease and at one point he had to carry her up stairs. He also tells the story of his mother who had a back injury and didn’t want to live because of the pain. How his family members got relief is illuminating.

Our whole understanding and approach to pain has changed, with the acronym change from RICE to MEAT.

A newly approved drug Suzetrigine (Journavx) exploits the sodium channel gene mutation initially discovered via a family of fire walkers. It’s the first new pain medicine approved for more than 2 decades. Many other new non-opioid treatments are reviewed, no less lifestyle changes (anti-inflammatory diet and sleep), and acupuncture.

Sanjay’s research over the past few years has led to a video special on CNN with the same title as the book, set to air 9 PM EST Sunday.

If you know someone suffering chronic pain, please share the post.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Mike Osterholm & Eric Topol - Discuss “The Big One” book03 sept. 202500:36:12


Get full access to Ground Truths at erictopol.substack.com/subscribe
Bruce Lanphear: Chronic Lead Exposure, a Risk Factor for Heart Disease17 août 202500:25:53

This is a hybrid heart disease risk factor post of a podcast with Prof Bruce Lanphear on lead and a piece I was asked to write for the Washington Post on risk factors for heart disease.

First, the podcast. You may have thought the problem with lead exposure was circumscribed to children, but it’s a much bigger issue than that. I’ll concentrate on the exposure risk to adults in this interview, including the lead-estrogen hypothesis. Bruce has been working on the subject of lead exposure for more than 30 years.

Let me emphasize that the problem is not going away, as highlighted in a recent New England Journal of Medicine piece on lead contamination in Milwaukee schools, “The Latest Episode in an Ongoing Toxic Pandemic.”

Transcript with links to the audio and citations

Eric Topol (00:05):

Well, hello. This is Eric Topol with Ground Truths, and I'm very delighted to welcome Professor Bruce Lanphear from Simon Fraser University in British Columbia for a very interesting topic, and that's about lead exposure. We tend to think about lead poisoning with the Flint, Michigan, but there's a lot more to this story. So welcome, Bruce.

Bruce Lanphear (00:32):

Thank you, Eric. It's great to be here.

Eric Topol (00:33):

Yeah. So you had a New England Journal of Medicine (NEJM) Review in October last year, which was probably a wake up to me, and I'm sure to many others. We'll link to that, where you reviewed the whole topic, the title is called Lead Poisoning. But of course it's not just about a big dose, but rather chronic exposure. So maybe you could give us a bit of an overview of that review that you wrote for NEJM.

Bruce Lanphear (01:05):

Yeah, so we really focused on the things where we feel like there's a definitive link. Things like lead and diminished IQ in children, lead and coronary heart disease, lead and chronic renal disease. As you mentioned, we've typically thought of lead as sort of the overt lead poisoning where somebody becomes acutely ill. But over the past century what we've learned is that lead is one of those toxic chemicals where it's the chronic wear and tear on our bodies that catches up and it's at the root of many of these chronic diseases that are causing problems today.

Eric Topol (01:43):

Yeah, it's pretty striking. The one that grabbed me and kind of almost fell out of my chair was that in 2019 when I guess the most recent data there is 5.5 million cardiovascular deaths ascribed to relatively low levels, or I guess there is no safe level of lead exposure, that's really striking. That's a lot of people dying from something that cardiology and medical community is not really aware of. And there's a figure 3 [BELOW] that we will also show in the transcript, where you show the level where you start to see a takeoff. It starts very low and by 50 μg/liter, you're seeing a twofold risk and there's no threshold, it keeps going up. How many of us do you think are exposed to that type of level as adults, Bruce?

Bruce Lanphear (02:39):

Well, as adults, if we go back in time, all of us. If you go back to the 1970s when lead was still in gasoline, the median blood lead level of Americans was about 13 to 15 µg/dL. So we've all been exposed historically to those levels, and part of the reason we've begun to see a striking decline in coronary heart disease, which peaked in 1968. And by 1978, there was a 20% decline, 190,000 more people were alive than expected. So even in that first decade, there was this striking decline in coronary heart disease. And so, in addition to the prospective studies that have found this link between an increase in lead exposure and death from cardiovascular disease and more specifically coronary heart disease. We can look back in time and see how the decline in leaded gasoline led to a decline in heart disease and hypertension.

Eric Topol (03:41):

Yeah, but it looks like it's still a problem. And you have a phenomenal graph that's encouraging, where you see this 95% reduction in the lead exposure from the 1970s. And as you said, the factors that can be ascribed to like getting rid of lead from gasoline and others. But what is troubling is that we still have a lot of people that this could be a problem. Now, one of the things that was fascinating is that you get into that herbal supplements could be a risk factor. That we don't do screening, of course, should we do screening? And there's certain people that particularly that you consider at high risk that should get screened. So I wasn't aware, I mean the one type of supplements that you zoomed in on, how do you say it? Ayurvedic?

Supplements With Lead

Bruce Lanphear (04:39):

Oh yeah. So this is Ayurvedic medicine and in fact, I just was on a Zoom call three weeks ago with a husband and wife who live in India. The young woman had taken Ayurvedic medicine and because of that, her blood lead levels increased to 70 µg/dL, and several months later she was pregnant, and she was trying to figure out what to do with this. Ayurvedic medicine is not well regulated. And so, that's one of the most important sources when we think about India, for example. And I think you pointed out a really important thing is number one, we don't know that there's any safe level even though blood lead levels in the United States and Europe, for example, have come down by over 95%. The levels that we're exposed to and especially the levels in our bones are 10 to 100 times higher than our pre-industrial ancestors.

Bruce Lanphear (05:36):

So we haven't yet reached those levels that our ancestors were exposed to. Are there effects at even lower and lower levels? Everything would suggest, we should assume that there is, but we don't know down below, let's say one microgram per deciliter or that's the equivalent of 10 parts per billion of lead and blood. What we also know though is when leaded gasoline was restricted in the United States and Canada and elsewhere, the companies turned to the industrializing countries and started to market it there. And so, we saw first the epidemic of coronary heart disease in the United States, Canada, Europe. Then that's come down over the past 50 years. At the same time, it was rising in low to middle income countries. So today over 95% of the burden of disease from lead including heart disease is found in industrializing countries.

Eric Topol (06:34):

Right. Now, it's pretty striking, of course. Is it true that airlines fuel is still with lead today?

Bruce Lanphear (06:45):

Well, not commercial airlines. It's going to be a small single piston aircraft. So for example, when we did a study down around the Santa Clara County Airport, Reid-Hillview, and we can see that the children who live within a half mile of the airport had blood lead levels about 10% higher than children that live further away. And the children who live downwind, 25% higher still. Now, nobody's mapped out the health effects, but one of the things that's particularly troubling about emissions from small aircraft is that the particle size of lead is extraordinarily small, and we know how nanoparticles because they have larger surface area can be more problematic. They also can probably go straight up into the brain or across the pulmonary tissues, and so those small particles we should be particularly worried about. But it's been such a long journey to try to figure out how to get that out of aircraft. It's a problem. The EPA recognized it. They said it's an endangerment, but the industry is still pushing back.

Eric Topol (07:55):

Yeah, I mean, it's interesting that we still have these problems, and I am going to in a minute ask you what we can do to just eradicate lead as much as possible, but we're not there yet. But one study that seemed to be hard to believe that you cited in the review. A year after a ban leaded fuel in NASCAR races, mortality from coronary heart disease declined significantly in communities near racetracks. Can you talk about that one because it's a little bit like the one you just mentioned with the airpo…



Get full access to Ground Truths at erictopol.substack.com/subscribe
Owen Tripp: Why Can't I Find and Get to the Right Doctor?13 juil. 202500:32:27

Eric Topol (00:06):

Hello, this is Eric Topol from Ground Truths, and I'm delighted to welcome Owen Tripp, who is a CEO of Included Health. And Owen, I'd like to start off if you would, with the story from 2016, because really what I'm interested in is patients and how to get the right doctor. So can you tell us about when you lost your hearing in your right ear back, what, nine years ago or so?

Owen Tripp (00:38):

Yeah, it's amazing to say nine years, Eric, but obviously as your listeners will soon understand a pretty vivid memory in my past. So I had been working as I do and noticed a loss of hearing in my right ear. I had never experienced any hearing loss before, and I went twice actually to a sort of national primary care chain that now owned by Amazon actually. And they described it as eustachian tube dysfunction, which is a pretty benign common thing that basically meant that my tubes were blocked and that I needed to have some drainage. They recommended Sudafed to no effect. And it was only a couple weeks later where I was walking some of the senior medical team at my company down to the San Francisco Giants game. And I was describing this experience of hearing loss and I said I was also losing a little bit of sensation in the right side of my face. And they said, that is not eustachian tube dysfunction. And well, I can let the story unfold from there. But basically my colleagues helped me quickly put together a plan to get this properly diagnosed and treated. The underlying condition is called vestibular schwannoma, even more commonly known as an acoustic neuroma. So a pretty rare benign brain tumor that exists on the vestibular nerve, and it would've cost my life had it not been treated.

Eric Topol (02:28):

So from what I gather, you saw an ENT physician, but that ENT physician was not really well versed in this condition, which is I guess a bit surprising. And then eventually you got to the right ENT physician in San Francisco. Is that right?

Owen Tripp (02:49):

Well, the first doctor was probably an internal medicine doctor, and I think it's fair to say that he had probably not seen many, if any cases. By the time I reached an ENT, they were interested in working me up for what's known as sudden sensorineural hearing loss (SSHL), which is basically a fancy term for you lose hearing for a variety of possible pathologies and reasons, but you go through a process of differential diagnosis to understand what's actually going on. By the time that I reached that ENT, the audio tests had showed that I had significant hearing loss in my right ear. And what an MRI would confirm was this mass that I just described to you, which was quite large. It was already about a centimeter large and growing into the inner ear canal.

Eric Topol (03:49):

Yeah, so I read that your Stanford brain scan suggested it was about size of a plum and that you then got the call that you had this mass in your brainstem tumor. So obviously that's a delicate operation to undergo. So the first thing was getting a diagnosis and then the next thing was getting the right surgeon to work on your brain to resect this. So how did you figure out who was the right person? Because there's only a few thousand of these operations done every year, as I understand.

Owen Tripp (04:27):

That's exactly right. Yeah, very few. And without putting your listeners to sleep too early in our discussion, what I'll say is that there are a lot of ways that you can actually do this. There are very few cases, any approach really requires either shrinking or removing that tumor entirely. My size of tumor meant it was really only going to be a surgical approach, and there I had to decide amongst multiple potential approaches. And this is what's interesting, Eric, you started saying you wanted to talk about the patient experience. You have to understand that I'm somebody, while not a doctor, I lead a very large healthcare company. We provide millions of visits and services per year on very complex medical diagnoses down to more standard day-to-day fare. And so, being in the world of medical complexity was not daunting on the basics, but then I'm the patient and now I have to make a surgical treatment decision amongst many possible choices, and I was able to get multiple opinions.

Owen Tripp (05:42):

I got an opinion from the House clinic, which is closer to you in LA. This is really the place where they invented the surgical approach to treating these things. I also got an approach shared with me from the Mayo Clinic and one from UCSF and one from Stanford, and ultimately, I picked the Stanford team. And these are fascinating and delicate structures as you know that you're dealing with in the brain, but the surgery is a long surgery performed by multiple surgeons. It's such an exhausting surgery that as you're sort of peeling away that tumor that you need relief. And so, after a 13 hour surgery, multiple nights in the hospital and some significant training to learn how to walk and move and not lose my balance, I am as you see me today, but it was possible under one of the surgical approaches that I would've lost the use of the right side of my face, which obviously was not an option given what I given what I do.

Eric Topol (06:51):

Yeah, well, I know there had to be a tough rehab and so glad that you recovered well, and I guess you still don't have hearing in that one ear, right?

Owen Tripp:

That's right.

Eric Topol:

But otherwise, you're walking well, and you've completely recovered from what could have been a very disastrous type of, not just the tumor itself, but also the way it would be operated on. 13 hours is a long time to be in the operating room as a patient.

Owen Tripp (07:22):

You've got a whole team in there. You've got people testing nerve function, you've got people obviously managing the anesthesiology, which is sufficiently complex given what's involved. You've got a specialized ENT called a neurotologist. You've got the neurosurgeon who creates access. So it's quite a team that does these things.

Eric Topol (07:40):

Yeah, wow. Now, the reason I wanted to delve into this from your past is because I get a call or email or whatever contact every week at least one, is can you help me find the right doctor for such and such? And this has been going on throughout my career. I mean, when I was back in 20 years ago at Cleveland Clinic, the people on the board, I said, well, I wrote about it in one of my books. Why did you become a trustee on the board? And he said, so I could get access to the right doctor. And so, this is amazing. We live in an information era supposedly where people can get information about this being the most precious part, which is they want to get the right diagnosis, they want to get the right treatment or prevention, whatever, and they can't get it. And I'm finding this just extraordinary given that we can do deep research through several different AI models and get reports generated on whatever you want, but you can't get the right doctor. So now let's go over to what you're working on. This company Included Health. When did you start that?

Owen Tripp (08:59):

Well, I started the company that was known as Grand Rounds in 2011. And Grand Rounds still to this day, we've rebranded as Included Health had a very simple but powerful idea, one you just obliquely referred to, which is if we get people to higher quality medicine by helping them find the right level and quality of care, that two good things would happen. One, the sort of obvious one, patients would get better, they'd move on with their lives, they'd return to health. But two and critically that we would actually help the system overall with the cost burden of unnecessary, inappropriate and low quality care because the coda to the example you gave of people calling you looking for a physician referral, and you and I both know this, my guess is you've probably had to clean plenty of it up in your career is if you go to the wrong doctor, yo…



Get full access to Ground Truths at erictopol.substack.com/subscribe
Priscilla Chan & Jennifer Doudna: New Center for Pediatric CRISPR Cures08 juil. 202500:23:08

Eric Topol (00:05):

Hello, it's Eric Topol from Ground Truths, and I've got some really exciting stuff to talk to you about today. And it's about the announcement for a new Center for pediatric CRISPR Cures. And I'm delight to introduce doctors Jennifer Doudna and Priscilla Chan. And so, first let me say this is amazing to see this thing going forward. It's an outgrowth of a New England Journal paper and monumental report on CRISPR in May. [See the below post for more context]

Let me introduce first, Dr. Doudna. Jennifer is the Li Ka Shing Chancellor's Chair and a Professor in the departments of chemistry and of molecular and cell biology at the University of California Berkeley. She's also the subject of this book, one of my favorite books of all time, the Code Breaker. And as you know, the 2020 Nobel Prize laureate for her work in CRISPR-Cas9 genome editing, and she founded the Innovative Genomics Institute (IGI) back 10 years ago. So Jennifer, welcome.

Jennifer Doudna (01:08):

Thank you, Eric. Great to be here.

Eric Topol (01:10):

And now Dr. Priscilla Chan, who is the co-founder of the Chan Zuckerberg Initiative (CZI) that also was started back in 2015. So here we are, a decade later, these two leaders. She is a pediatrician having trained at UCSF and is committed to the initiative which has as its mission statement, “to make it possible to cure, prevent, and manage all diseases in this century.” So today we're going to talk about a step closer to that. Welcome, Priscilla.

Priscilla Chan (01:44):

Thank you. Thanks for having me.

Eric Topol (01:46):

Alright, so I thought we'd start off by, how did you two get together? Have you known each other for over this past decade since you both got all your things going?

Jennifer Doudna (01:56):

Yes, we have. We've known each other for a while. And of course, I've admired the progress at the CZI on fundamental science. I was an advisor very early on and I think actually that's how we got to know each other. Right, Priscilla?

Priscilla Chan (02:11):

Yeah, that's right. We got to know each other then. And we've been crisscrossing paths. And I personally remember the day you won the Nobel Prize. It was in the heart of the pandemic and a lot of celebrations were happening over Zoom. And I grabbed my then 5-year-old and got onto the UCSF celebration and I was like, look, this is happening. And it was really cool for me and for my daughter.

Eric Topol (02:46):

Well, it's pretty remarkable convergence leading up to today's announcement, but I know Priscilla, that you've been active in this rare disease space, you've had at CZI a Rare As One Project. Maybe you could tell us a bit about that.

Priscilla Chan (03:01):

Yeah, so at CZI, we work on basic science research, and I think that often surprises people because they know that I'm a pediatrician. And so, they often think, oh, you must work in healthcare or healthcare delivery. And we've actually chosen very intentionally to work in basic science research. In part because my training as a pediatrician at UCSF. As you both know, UCSF is a tertiary coronary care center where we see very unusual and rare cases of pediatric presentations. And it was there where I learned how little we knew about rare diseases and diseases in general and how powerful patients were. And that research was the pipeline for hope and for new discoveries for these families that often otherwise don't have very much access to treatments or cures. They have a PDF that maybe describes what their child has. And so, I decided to invest in basic science through CZI, but always saw the power of bringing rare disease patient cohorts. One, because if you've ever met a parent of a child with rare disease, they are a force to be reckoned with. Two, they can make research so much better due to their insights as patients and patient advocates. And I think they close the distance between basic science and impact in patients. And so, we've been working on that since 2019 and has been a passion of ours.

Eric Topol (04:40):

Wow, that's great. Now Jennifer, this IGI that you founded a decade ago, it's doing all kinds of things that are even well beyond rare diseases. We recently spoke, I know on Ground Truths about things as diverse as editing the gut microbiome in asthma and potentially someday Alzheimer’s. But here you were very much involved at IGI with the baby KJ Muldoon. Maybe you could take us through this because this is such an extraordinary advance in the whole CRISPR Cures story.

Jennifer Doudna (05:18):

Yes, Eric. It's a very exciting story and we're very, very proud of the teamwork that went into making it possible to cure baby KJ of his very rare disease. And in brief, the story began back in August of last year when he was born with a metabolic disorder that prevented him from digesting protein, it's called a urea cycle disorder and rare, but extremely severe. And to the point where he was in the ICU and facing a very, very difficult prognosis. And so, fortunately his clinical team at Children's Hospital of Philadelphia (CHOP) reached out to Fyodor Urnov, who is the Director of Translational Medicine at the IGI here in the Bay Area. They teamed up and realized that they could quickly diagnose that child because we had an IRB approved here at the IGI that allowed us to collect patient samples and do diagnosis. So that was done.

Jennifer Doudna (06:26):

We created an off-the-shelf CRISPR therapy that would be targeted to the exact mutation that caused that young boy's disease. And then we worked with the FDA in Washington to make sure that we could very safely proceed with testing of that therapy initially in the lab and then ultimately in two different animal models. And then we opened a clinical trial that allowed that boy to be enrolled with, of course his parents' approval and for him to be dosed and the result was spectacular. And in fact, he was released from the hospital recently as a happy, healthy child, gaining lots of weight and looking very chunky. So it's really exciting.

Eric Topol (07:16):

It's so amazing. I don't think people necessarily grasp this. This timeline [see above] that we'll post with this is just mind boggling how you could, as you said Jennifer, in about six months to go from the birth and sequencing through cell specific cultures with the genome mutations through multiple experimental models with non-human primates even, looking at off-target effects, through the multiple FDA reviews and then dosing, cumulatively three dosing to save this baby's life. It really just amazing. Now that is a template. And before we go to this new Center, I just wanted to also mention not just the timeline of compression, which is unimaginable and the partnership that you've had at IGI with I guess Danaher to help manufacture, which is just another part of the story. But also the fact that you're not just even with CRISPR 1.0 as being used in approvals previously for sickle cell and β-thalassemia, but now we're talking about base editing in vivo in the body using mRNA delivery. So maybe you could comment on that, Jennifer.

Jennifer Doudna (08:38):

Yeah, very good point. So yeah, we used a version of CRISPR that was created by David Liu at the Broad Institute and published and available. And so, it was possible to create that, again, targeted to the exact mutation that caused baby KJ’s disease. And fortunately, there was also an off-the-shelf way to deliver it because we had access to lipid nanoparticles that were developed for other purposes including vaccinations. And the type of disease that KJ suffered from is one that is treatable by editing cells in the liver, which is where the lipid nanoparticle naturally goes. So there were definitely some serendipity here, but it was amazing how all of these pieces were available. We just had to pull them together to create this therapy.

Eric Topol (09:30):

Yeah, no, it is amazing. So that I think is a great substrate for starting a new Center. And so, maybe back to you Pri…



Get full access to Ground Truths at erictopol.substack.com/subscribe
Adam Kucharski: The Uncertain Science of Certainty29 juin 202500:45:10

“To navigate proof, we must reach into a thicket of errors and biases. We must confront monsters and embrace uncertainty, balancing — and rebalancing —our beliefs. We must seek out every useful fragment of data, gather every relevant tool, searching wider and climbing further. Finding the good foundations among the bad. Dodging dogma and falsehoods. Questioning. Measuring. Triangulating. Convincing. Then perhaps, just perhaps, we'll reach the truth in time.”—Adam Kucharski

My conversation with Professor Kucharski on what constitutes certainty and proof in science (and other domains), with emphasis on many of the learnings from Covid. Given the politicization of science and A.I.’s deepfakes and power for blurring of truth, it’s hard to think of a topic more important right now.

Audio file (Ground Truths can also be downloaded on Apple Podcasts and Spotify)

Eric Topol (00:06):

Hello, it's Eric Topol from Ground Truths and I am really delighted to welcome Adam Kucharski, who is the author of a new book, Proof: The Art and Science of Certainty. He’s a distinguished mathematician, by the way, the first mathematician we've had on Ground Truths and a person who I had the real privilege of getting to know a bit through the Covid pandemic. So welcome, Adam.

Adam Kucharski (00:28):

Thanks for having me.

Eric Topol (00:30):

Yeah, I mean, I think just to let everybody know, you're a Professor at London School of Hygiene and Tropical Medicine and also noteworthy you won the Adams Prize, which is one of the most impressive recognitions in the field of mathematics. This is the book, it's a winner, Proof and there's so much to talk about. So Adam, maybe what I'd start off is the quote in the book that captivates in the beginning, “life is full of situations that can reveal remarkably large gaps in our understanding of what is true and why it's true. This is a book about those gaps.” So what was the motivation when you undertook this very big endeavor?

Adam Kucharski (01:17):

I think a lot of it comes to the work I do at my day job where we have to deal with a lot of evidence under pressure, particularly if you work in outbreaks or emerging health concerns. And often it really pushes the limits, our methodology and how we converge on what's true subject to potential revision in the future. I think particularly having a background in math’s, I think you kind of grow up with this idea that you can get to these concrete, almost immovable truths and then even just looking through the history, realizing that often isn't the case, that there's these kind of very human dynamics that play out around them. And it's something I think that everyone in science can reflect on that sometimes what convinces us doesn't convince other people, and particularly when you have that kind of urgency of time pressure, working out how to navigate that.

Eric Topol (02:05):

Yeah. Well, I mean I think these times of course have really gotten us to appreciate, particularly during Covid, the importance of understanding uncertainty. And I think one of the ways that we can dispel what people assume they know is the famous Monty Hall, which you get into a bit in the book. So I think everybody here is familiar with that show, Let's Make a Deal and maybe you can just take us through what happens with one of the doors are unveiled and how that changes the mathematics.

Adam Kucharski (02:50):

Yeah, sure. So I think it is a problem that's been around for a while and it's based on this game show. So you've got three doors that are closed. Behind two of the doors there is a goat and behind one of the doors is a luxury car. So obviously, you want to win the car. The host asks you to pick a door, so you point to one, maybe door number two, then the host who knows what's behind the doors opens another door to reveal a goat and then ask you, do you want to change your mind? Do you want to switch doors? And a lot of the, I think intuition people have, and certainly when I first came across this problem many years ago is well, you've got two doors left, right? You've picked one, there's another one, it's 50-50. And even some quite well-respected mathematicians.

Adam Kucharski (03:27):

People like Paul Erdős who was really published more papers than almost anyone else, that was their initial gut reaction. But if you work through all of the combinations, if you pick this door and then the host does this, and you switch or not switch and work through all of those options. You actually double your chances if you switch versus sticking with the door. So something that's counterintuitive, but I think one of the things that really struck me and even over the years trying to explain it is convincing myself of the answer, which was when I first came across it as a teenager, I did quite quickly is very different to convincing someone else. And even actually Paul Erdős, one of his colleagues showed him what I call proof by exhaustion. So go through every combination and that didn't really convince him. So then he started to simulate and said, well, let's do a computer simulation of the game a hundred thousand times. And again, switching was this optimal strategy, but Erdős wasn't really convinced because I accept that this is the case, but I'm not really satisfied with it. And I think that encapsulates for a lot of people, their experience of proof and evidence. It's a fact and you have to take it as given, but there's actually quite a big bridge often to really understanding why it's true and feeling convinced by it.

Eric Topol (04:41):

Yeah, I think it's a fabulous example because I think everyone would naturally assume it's 50-50 and it isn't. And I think that gets us to the topic at hand. What I love, there's many things I love about this book. One is that you don't just get into science and medicine, but you cut across all the domains, law, mathematics, AI. So it's a very comprehensive sweep of everything about proof and truth, and it couldn't come at a better time as we'll get into. Maybe just starting off with math, the term I love mathematical monsters. Can you tell us a little bit more about that?

Adam Kucharski (05:25):

Yeah, this was a fascinating situation that emerged in the late 19th century where a lot of math’s, certainly in Europe had been derived from geometry because a lot of the ancient Greek influence on how we shaped things and then Newton and his work on rates of change and calculus, it was really the natural world that provided a lot of inspiration, these kind of tangible objects, tangible movements. And as mathematicians started to build out the theory around rates of change and how we tackle these kinds of situations, they sometimes took that intuition a bit too seriously. And there was some theorems that they said were intuitively obvious, some of these French mathematicians. And so, one for example is this idea of you how things change smoothly over time and how you do those calculations. But what happened was some mathematicians came along and showed that when you have things that can be infinitely small, that intuition didn't necessarily hold in the same way.

Adam Kucharski (06:26):

And they came up with these examples that broke a lot of these theorems and a lot of the establishments at the time called these things monsters. They called them these aberrations against common sense and this idea that if Newton had known about them, he never would've done all of his discovery because they're just nuisances and we just need to get rid of them. And there's this real tension at the core of mathematics in the late 1800s where some people just wanted to disregard this and say, look, it works for most of the time, that's good enough. And then others really weren't happy with this quite vague logic. They wanted to put it on much sturdier ground. And what was remarkable actually is if you trace this then into the 20th century, a lot of these monsters and these particularly in some cases functions which could almost move c…



Get full access to Ground Truths at erictopol.substack.com/subscribe
Eric Topol With Devi Sridhar on her new book- How Not to Die (Too Soon) 17 juin 202500:37:51

Thanks to so many of you who joined our live conversation with Devi Sridhar!

Professor Devi Sridhar is the Chair of Global Public Health at the University of Edinburgh. Over the past 2 decades she has become one of the world’s leading authorities and advisors for promoting global health. Her new book —How No to Die Too Soon—provides a unique outlook for extending healthspan with a global perspective admixed with many personal stories.

We talked about lifestyle factors with lessons from Japan (on diet) and the Netherlands (on physical activity), ultra-processed foods, air pollution and water quality, the prevention model in Finland, guns, inequities, the US situation for biomedical research and public health agency defunding, and much more.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Matthew Walker: Promoting Our Sleep Health14 juin 202500:37:41

My conversation with Matthew Walker, PhD on faculty at UC Berkeley where he is a professor of neuroscience and psychology, the founder and director of the Center for Human Sleep Science, and has a long history of seminal contributions on sleep science and health.

Audio File (also downloadable at Apple Podcast and Spotify)

“Sleep is a non-negotiable

biological state required for the maintenance of human life . . . our needs

for sleep parallel those for air, food, and water.”—Grandner and Fernandez

Eric Topol (00:07):

Hello, it's Eric Topol with Ground Truths, and I am really delighted to welcome Matt Walker, who I believe has had more impact on sleep health than anyone I know. It's reflected by the fact that he is a Professor at UC Berkeley, heads up the center that he originated for Human Sleep Science. He wrote a remarkable book back in 2017, Why We Sleep, and also we'll link to that as well as the TED Talk of 2019. Sleep is Your Superpower with 24 million views. That's a lot of views here.

Matt Walker:

Striking, isn't it?

Eric Topol:

Wow. I think does reflect the kind of impact, you were onto the sleep story sooner, earlier than anyone I know. And what I wanted to do today was get to the updates because you taught us a lot back then and a lot of things have been happening in these years since. You're on it, of course, I think you have a podcast Sleep Diplomat, and you're obviously continued working on the science of sleep. But maybe the first thing I'd ask you about is in the last few years, what do you think has been, are there been any real changes or breakthroughs in the field?

What Is New?

Matt Walker (01:27):

Yeah, I think there has been changes, and maybe we'll speak about one of them, which is the emergence of this brain cleansing system called the glymphatic system, but spreading that aside for potential future discussion. I would say that there are maybe at least two fascinating areas. The first is the broader impact of sleep on much more complex human social interactions. We think of sleep at maybe the level of the cell or systems or whole scale biology or even the entire organism. We forget that a lack of sleep, or at least the evidence suggests a lack of sleep will dislocate each other, one from the other. And there's been some great work by Dr. Eti Ben Simon for example, demonstrating that when you are sleep deprived, you become more asocial. So you basically become socially repellent. You want to withdraw, you become lonely. And what's also fascinating is that other people, even they don't know that you sleep deprived, they rate you as being less socially sort of attractive to engage with.

Matt Walker (02:35):

And after interacting with you, the sleep deprived individual, even though they don't know you're sleep deprived, they themselves walk away feeling more lonely themselves. So there is a social loneliness contagion that happens that a sleep deprived lonely individual can have almost a viral knock on effect that causes loneliness in another well-rested individual. And then that work spanned out and it started to demonstrate that another impact of a lack of sleep socially is that we stop wanting to help other people. And you think, well, helping behavior that's not really very impactful. Try to tell me of any major civilization that has not risen up through human cooperation and helping. There just isn't one. Human cooperative behavior is one of our innate traits as homo sapiens. And what they discovered is that when you are insufficiently slept, firstly, you don't wish to help other people. And you can see that at the individual level.

Matt Walker (03:41):

You can see it in groups. And then there was a great study again by Dr. Eti Ben Simon that demonstrated this at a national level because what she did was she looked at this wonderful manipulation of one hour of sleep that happens twice a year to 1.6 billion people. It's called daylight savings time at spring. Yeah, when you lose one hour of sleep opportunity. She looked at donations across the nation and sure enough, there was this big dent in donation giving in the sleepy Monday and Tuesday after the clock change. Because of that sleep, we become less willing to empathetically and selflessly help other individuals. And so, to me I think it's just a fascinating area. And then the other area I think is great, and I'm sorry I'm racing forward because I get so excited. But this work now looking at what we call genetic short sleepers and sort of idiots like me have been out there touting the importance of somewhere between seven to nine hours of sleep.

Matt Walker (04:48):

And once you get less than that, and we'll perhaps speak about that, you can see biological changes. But there is a subset of individuals who, and we've identified at least two different genes. One of them is what we call the DEC2 gene. And it seems to allow individuals to sleep about five hours, maybe even a little bit less and show no impairment whatsoever. Now we haven't tracked these individuals across the lifespan to truly understand does it lead to a higher mortality risk. But so far, they don't implode like you perhaps or I would do when you are limited to this anemic diet of five hours of sleep. They hang in there just fine. And I think philosophically what that tells me, and by the way, for people who are listening thinking, gosh, I think I'm probably one of those people. Statistically, I think you are more likely to be struck by lightning in your lifetime than you are to have the DEC2 gene. Think about what tells us, Eric. It tells us that there is a moment in biology in the evolution of this thing called the sleep physiological need that has changed such that mother nature has found a genetic way to ZIP file sleep.

Matt Walker (06:14):

You can essentially compress sleep from seven to nine hour need, down to five to six hour need. To me, that is absolutely fascinating. So now the race is on, what are the mechanisms that control this? How do we understand them? I'm sure much to my chagrin, society would like to then say, okay, is there a pill that I can take to basically ZIP file my own sleep and then it becomes an arms race in my mind, which is then all of a sudden six hours becomes the new eight hours and then everyone is saying, well, six hours is my need. Well I'll go to four hours and then it's this arms race of de-escalation of sleep. Anyway, I'm going on and on, does that help give you a sense of two of the what I feel the more fascinating areas?

Eric Topol (07:01):

Absolutely. When I saw the other recent report on the short sleep gene variant and thought about what the potential of that would be with respect to potential drug development or could you imagine genome editing early in life that you don't need any sleep? I mean crazy stuff.

Matt Walker (07:19):

It was amazing.

Glymphatics and Deep Sleep

for more, see previous Ground Truths on this topic

Eric Topol (07:22):

No, the mechanism of course we have to work out and also what you mentioned regarding the social and the behavior engagement, all that sort of thing, it was just fascinating stuff. Now we touched on one thing early on to come back to the glymphatics these channels to get rid of the waste metabolites from the brain each night that might be considered toxic metabolites. We've learned a lot about those and of course there's some controversy about it. What are your thoughts?

Matt Walker (07:55):

Yeah, I think there's really quite comprehensive evidence suggesting that the brain has this cleansing system like the body has one the lymphatic system, the brain has one the glymphatic system named after these glial cells that make it up. And I think there's been evidence from multiple groups across multiple different species types, from mouse models all the way up to human models suggesting that there is a state dependent control of the brain cleansing system, which is a fancy way of saying if you are awake in light NREM, deep NREM or perhaps you're just quiet and yo…



Get full access to Ground Truths at erictopol.substack.com/subscribe
Katie Couric and Eric Topol: On the State of US Life Science and Extending Healthspan12 juin 202500:54:32

Thank you Richard DeWald, Michael Mann, Dr Avneesh Khare, Maud Pasturaud, Lower Dementia Risk, and many others for tuning into my live video with Katie Couric! Join me for my next live video in the app.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Sir John Bell: Transforming Life Science and Medicine's Future26 mai 202500:33:15

Audio File

Ground Truths can also be found on Apple Podcasts, Spotify and YouTube.

The UK is the world leader in human genomics, and laid the foundation for advancing medicine with the UK Biobank, Genomes England and now Our Future Health (w/ 5 million participants). Sir John Bell is a major force in driving and advising these and many other initiatives. After 22 years as the Regius Professor of Medicine at the University of Oxford he left in 2024 to be President of the Ellison Institute of Technology.

Professor Bell has been duly recognized in the UK: knighted in 2015 and appointed Companion of Honor in 2023.

In our conversation, you will get a sense for how EIT will be transformational for using A.I. and life science for promoting human health.

Transcript with audio links

Eric Topol (00:06):

Hello, this is Eric Topol from Ground Truths. And I'm really delighted to welcome today, Sir John Bell who had an extraordinary career as a geneticist, immunologist, we'll talk about several initiatives he's been involved with during his long tenure at University of Oxford, recently became head of the Ellison Institute of Technology (EIT) in the UK. So welcome, John.

Sir John Bell (00:30):

Thanks, Eric. Thanks very much for having me.

Eric Topol (00:34):

Well, I think it's just extraordinary the contributions that you have made and continue to make to advance medicine, and I thought what we could do is get into that. I mean, what's interesting, you have had some notable migrations over your career, I think starting in Canada, at Stanford, then over as Rhodes Scholar in Oxford. And then you of course had a couple of decades in a very prestigious position, which as I understand was started in 1546 by King Henry VII, and served as the Regius Professor of Medicine at the University of Oxford. Do I have that right?

Sir John Bell (01:11):

It was actually Henry VIII, but you were close.

Eric Topol (01:14):

Henry VIII, that's great. Yeah. Okay, good. Well, that's a pretty notable professorship. And then of course in recent times you left to head up this pretty formidable new institute, which is something that's a big trend going on around the world, particularly in the US and we'll talk about. So maybe we can start with the new thing. Tell us more about the Ellison Institute of Technology (EIT), if you will.

Sir John Bell (01:47):

Yeah. So as you know, Larry Ellison has been one of the great tech entrepreneurs focused really on developing terrific databases over his career and through Oracle, which is the company that he founded. And Larry is really keen to try and give back something substantial to the world, which is based on science and technology. So he and I did quite a bit together over the Covid pandemic. He and I talked a lot about what we're doing and so on. He came to visit afterwards and he had, I think he decided that the right way to make his contributions would be to set up an institute that would be using the state-of-the-art science and technology with a lot of AI and machine learning, but also some of the other modern tools to address the major problems in healthcare, in food security, in green energy and climate change and in global governance.

Sir John Bell (02:49):

So anyway, he launched this about 18 months ago. He approached me to ask whether I would run it. He wanted to set it up outside Oxford, and he wanted to do something which is a bit different than others. And that is his view was that we needed to try and create solutions to these problems which are commercially viable and not all the solutions are going to be commercially viable, but where you can create those, you make them sustainable. So the idea is to make sure that we create solutions that people want to buy, and then if they buy them, you can create a sustainable solution to those issues. So we are actually a company, but we are addressing many of the same problems that the big foundations are addressing. And the big issues that you and I talk about in health, for example, are all on our list. So we're kind of optimistic as to where this will go and Larry's supporting the project and we're going to build out an institute here which will have about 5,000 people in it, and we'll be, I think a pretty exciting new addition to the science and technology ecosystem globally.

Eric Topol (04:02):

Well, I know the reverberations and the excitement is palpable and some of the colleagues I've spoken to, not just in England, but of course all over the world. So congratulations on that. It was a big move for you to leave the hardcore academics. And the other thing I wanted to ask you, John, is you had distinguished your career in immunology, in genetics, type 1 diabetes and other conditions, autoimmune conditions, and now you've really diversified, as you described with these different areas of emphasis at the new institute. Is that more fun to do it or do you have deputies that you can assign to things like climate change in other areas?

Sir John Bell (04:50):

Trust me, Eric, I'm not making any definitive decisions about areas I know nothing about, but part of this is about how do you set up leadership, run a team, get the right people in. And I have to say one of the really interesting things about the institute is we've been able to recruit some outstanding people across all those domains. And as you know, success is almost all dependent on people. So we're really pretty optimistic we're going to have a significant impact. And of course, we also want to take risks because not a lot of point in us doing stuff that everybody else is doing. So we're going to be doing some things that are pretty way out there and some of them will fail, so we are just going to get used to trying to make sure we get a few of them across the finish line. But the other thing is that, and you've experienced this too, you never get too old to learn. I mean, I'm sucking up stuff that I never thought I would ever learn about, which is fun actually, and really marvel.

Eric Topol (05:55):

It's fantastic. I mean, you've really broadened and it's great that you have the runway to get these people on board and I think you're having a big building that's under construction?

Sir John Bell (06:07):

Yeah, we've got the original building that Larry committed to is about 330,000 square feet of space. I mean, this is completely amazing, but we are of course to accommodate up to 5,000 people, we're going to need more than that. So we are looking at a much wider campus here that'll involve more than just that building. I think we'll end up with several million square feet of space by the time we're finished. So mean, it's a really big project, but we've already made progress in some domains to try and get projects and the beginnings of companies on the road to try and solve some of the big problems. So we're quite excited about it.

Eric Topol (06:49):

Now you, I assume it's pretty close to Oxford, and will you have some kind of inter interactions that are substantial?

Sir John Bell (06:58):

Yeah, so the university's been terrific about this actually, because of course most universities would say, well, why don't you do it inside the university and just give us the money and it'll all be fine. So of course Larry. Larry wasn't born yesterday, so I said, well, thank you very much, but I think we'll probably do this nearby. But the university also realized this is a really exciting opportunity for them and we've got a really good relationship with them. We've signed an agreement with them as to who will work where. We've agreed not to steal a lot of their staff. We're going to be bringing new people into the ecosystem. Some of the university people will spend some time with us and sometime in the university, so that will help. But we're also bringing quite a few new people into the setting. So the university has been really positive. And I thi…



Get full access to Ground Truths at erictopol.substack.com/subscribe
Tyler Cowen: The Prototypic Polymath10 mai 202500:32:18

Audio file, also on Apple and Spotify

Tyler Cowen, Ph.D, is the Holbert L. Harris Professor of Economics at George Mason University. He is the author of 17 books, most recently Talent.: How to Identify Energizers, Creatives, and Winners Around the World. Tyler has been recognized as one of the most influential economists of the past decade. He initiated and directs the philanthropic project Emergent Ventures, writes a blog Marginal Revolution, and a podcast Conversations With Tyler, and also writes columns for The Free Press." He is writing a new book (and perhaps his last) on Mentors.

“Maybe AGI [Artificial General Intelligence] is like porn — I know it when I see it. And I’ve seen it.”—Tyler Cowen

Our conversation on acquiring information, A.I., A.G.I., the NIH, the assault on science, the role of doctors in the A.I. era,, the meaning of life, books of the future, and much more.

Transcript with links

Eric Topol (00:06):

Well, hello. This is Eric Topol with Ground Truths, and I am really thrilled today to have the chance to have a conversation with Tyler Cowen, who is, when you look up polymath in the dictionary, you might see a picture of him. He is into everything. And recently in the Economist magazine 1843, John Phipps wrote a great piece profile, the man who wants to know everything. And actually, I think there's a lot to that.

Tyler Cowen (00:36):

That's why we need longevity work, right?

Eric Topol (00:39):

Right. So he's written a number of books. How many books now, Tyler?

Tyler Cowen:

17, I'm not sure.

Eric Topol:

Only 17? And he also has a blog that's been going on for over 20 years, Marginal Revolution that he does with Alex Tabarrok.

Tyler Cowen (00:57):

Correct.

Eric Topol (00:57):

And yeah, and then Conversations with Tyler, a podcast, which I think an awful lot of people are tuned into that. So with that, I'm just thrilled to get a chance to talk with you because I used to think I read a lot, but then I learned about you.

“Cowen calls himself “hyperlexic”. On a good day, he claims to read four or five

books. Secretly, I timed him at 30 seconds per page reading a dense tract by

Martin Luther. “—John Phipps, The Economist’s 1843

I've been reading more from the AIs lately and less from books. So I'll get one good book and ask the AI a lot of questions.

Eric Topol (01:24):

Yeah. Well, do you use NotebookLM for that?

Tyler Cowen (01:28):

No, just o3 from OpenAI at the moment, but a lot of the models are very good. Claude, there's others.

Eric Topol (01:35):

Yeah, yeah. No, I see how that's a whole different way to interrogate a book and it's great. And in fact, that gets me to a topic I was going to get to later, but I'll do it now. You're soon or you have already started writing for the Free Press with Barri Weiss.

Tyler Cowen (01:54):

That’s right, yes. I have a piece coming out later today. It's been about two weeks. It's been great so far.

“Tyler Cowen has a mind unlike any I've ever encountered. In a single conversation, it’s not at all unusual for him to toggle between DeepSeek, GLP-1s, Haitian art, sacred Tibetan music, his favorite Thai spot in L.A., and LeBron James”—Bari Weiss

Yeah, so that's interesting. I hadn't heard of it until I saw the announcement from Barri and I thought what was great about it is she introduced it. She said, “Tyler Cowen has a mind unlike any I've ever encountered. In a single conversation, it’s not at all unusual for him to toggle between DeepSeek, GLP-1s, Haitian art, sacred Tibetan music, his favorite Thai spot in L.A., and LeBron James. Now who could do that, right. So I thought, well, you know what? I need independent confirmation of that, that is as being a polymath. And then I saw Patrick Collison, who I know at Stripe and Arc Institute, “you can have a specific and detailed discussion with him about 17th-century Irish economic thinkers, or trends in African music or the history of nominal GDP targeting. I don't know anyone who can engage in so many domains at the depth he does.” So you're an information acquirer and one of the books you wrote, I love the title Infovore.

Tyler Cowen (03:09):

The Age of the Infovore, that’s right.

Eric Topol (03:11):

I mean, have people been using that term because you are emblematic of it?

“You can have a specific and detailed discussion with him about 17th-century Irish economic thinkers, or trends in African music or the history of nominal GDP targeting. I don't know anyone who can engage in so many domains at the depth he does.”—Patrick Collison

It was used on the internet at some obscure site, and I saw it and I fell in love with that word, and I thought I should try to popularize it, but it doesn't come from me, but I think I am the popularizer of it.

Yeah, well, if anybody was ingesting more information and being able to work with it. That's what I didn't realize about you, Tyler, is restaurants and basketball and all these other fine arts, very impressive. Now, one of the topics I wanted to get into you is I guess related to a topic you've written about fair amount, which is the great stagnation, and right now we're seeing issues like an attack on science. And in the past, you've written about how you want to raise the social status of scientists. So how do you see this current, I would even characterize as a frontal assault on science?

Tyler Cowen (04:16):

Well, I'm very worried about current Trump administration policies. They change so frequently and so unpredictably, it's a little hard to even describe what they always are. So in that sense, it's a little hard to criticize them, but I think they're scaring away talent. They might scare away funding and especially the biomedical sciences, the fixed costs behind a lot of lab work, clinical trials, they're so high that if you scare money away, it does not come back very readily or very quickly. So I think the problem is biggest perhaps for a lot of the biomedical sciences. I do think a lot of reform there has been needed, and I hope somehow the Trump policies evolve to that sort of reform. So I think the NIH has become too high bound and far too conservative, and they take too long to give grants, and I don't like how the overhead system has been done. So there's plenty of room for improvement, but I don't see so far at least that the efforts have been constructive. They've been mostly destructive.

Eric Topol (05:18):

Yeah, I totally agree. Rather than creative destruction it’s just destruction and it's unfortunate because it seems to be haphazard and reckless to me at least. We of course, like so many institutions rely on NIH funding for the work, but I agree that reform is fine as long as it's done in a very thought out, careful way, so we can eke out the most productivity for the best investment. Now along with that, you started Emergent Ventures where you're funding young talent.

Tyler Cowen (05:57):

That's right. That's a philanthropic fund. And we now have slightly over 1000 winners. They're not all young, I'd say they're mostly young and a great number of them want to go into the biomedical sciences or have done so. And this is part of what made me realize what an incredible influx of talent we're seeing into those areas. I'm not sure this is widely appreciated by the world. I'm sure you see it. I also see how much of that talent actually is coming from Canada, from Ontario in particular, and I've just become far more optimistic about computational biology and progress in biology and medical cures, fixes, whatever you want to call it, extending lives. 10 years ago, I was like, yeah, who knows? A lot of things looked pretty stuck. Then we had a number of years where life expectancy was falling, and now I think we're on the verge of a true golden age.

Eric Topol (06:52):

I couldn't agree with you more on that. And I know some of the people that you funded like Anne Wylie who developed a saliva test for Covid out of Yale. But as you say, there's so many great young and maybe not so young…



Get full access to Ground Truths at erictopol.substack.com/subscribe
Bob Bordone and Joel Salinas: How to Deal With Conflict05 mai 202500:29:13

In our divided world we face or avoid conflicts on a frequent basis. I turned to Bob Bordone and Joel Salinas to find out the best strategies to deal with these, including having them take on a mock conflict between each other on the merits of Covid research.

Audio file

You can also find this on Spotify and Apple podcasts with Ground Truths.

The video is also posted on YouTube

Transcript with Audio Links

Eric Topol (00:06):

Well, hello. It's Eric Topol with Ground Truths, and we're going to get into a new book called Conflict Resilience: Negotiating Disagreement Without Giving Up or Giving In, and we're lucky to have its two authors, Bob Bordone, who is a Senior Fellow at Harvard Law School, and Joel Salinas, who is a physician, neurologist, a clinician scientist at NYU. So welcome both Bob and Joel.

Bob Bordone and Joel Salinas (00:34):

Thank you for having us. Yeah, looking forward to the conversation.

Eric Topol (00:37):

Yeah. So first, how did you guys get together? This is a pretty diverse, you got law and medicine, usually they don't talk to each other very much.

Bob Bordone (00:46):

Well, we were very fortunate. I mean, we basically were friends, but part of that friendship, I think emerged from work that I do around conflict issues in the Mass General system and then just the larger, bigger Mass General, Harvard community. Yeah, so this began really as a friendship where we were each swimming in very different waters, but then as we would start to talk, we realized there was a lot of connection and maybe the possibility to bring two different disciplines together in a way that might be practically useful and make an impact. And even when we started writing this, which was during Covid, what seemed to be some pretty polarizing times that were unlikely to resolve by the time the book would come out.

Eric Topol (01:44):

Yeah, well you sure hit it with the divisiveness and the polarized world that we live in is perhaps worse than ever, certainly in all my years, and probably long before then as well. So this topic of resilience, it's a very interesting concept because some people might think of resilience as just being tough. So go into a conflict and just go heavy tough. That obviously is not what you're writing about. And I guess maybe we can start off, what was the goal here? Obviously, there's other books that have addressed this topic, I'm sure, but yours is somewhat unique in many respects because it brings in the science of it and many strategies perhaps that have never been developed. But when you got together, what was the mission that you set out to do?

Joel Salinas (02:38):

Yeah, well maybe I can start out and then you can add on. So my research has been all around understanding how social relationships influenced brain health, and one of the things that I was seeing was social isolation and loneliness had been steadily increasing. Want to figure out what kind of interventions or what are the factors that are involved here? And I think one of the things that has stood out is just the difficulty with being able to navigate conflict in different contexts. And so, the idea around conflict resilience is really, even though there's been lots of books on what to say and what specific tactics to use, I think that there was this skillset around just being able to sit with the discomfort of that disagreement, which will ultimately help make it much more useful to take on those tactics. One way to think about it, if it's like all these tactics are like learning how to cook with a set of recipes in the kitchen, what we're really proposing here is that you also need to be able to stand the heat of the kitchen to even be able to cook.

Eric Topol (03:47):

Okay. Go ahead, Bob.

Bob Bordone (03:49):

Yeah, and I would say I was starting to write about my first kind of piece on this topic where I use the word conflict resilience was in 2018, and it really came from an observed dynamic that I was seeing in my teaching of Harvard Law School students. I was on the admissions committee, I'd been on the admissions committee for many years. I knew that we worked very hard and were quite successful in fact, at bringing together a very diverse student body, including politically. And people sometimes maybe think of elite law schools as being very progressive. But Harvard Law School, the biggest student organization is actually the Federalists, which is the conservative students. And despite that effort, what I noticed in the classroom was a reduction in conversation, diversity of viewpoint across the board, interesting classrooms became boring. And even though I was teaching around conflict and negotiation and difficult conversations, I would read in students' journals things like, I want to avoid conflict or I don't want to get into it.

Bob Bordone (04:59):

And so, it occurred to me that quite a part, as Joel said, from any skills, if we don't develop this capacity to sit with disagreement, then we will never get to problem solving. I'm in favor of problem solving. But this paper on conflict resilience, its original title was called Against Problem Solving. Mostly because I thought that if we had opened the possibility of problem solving as a precondition for entering the room, then we might never enter the room, particularly if we've told the demonized and dehumanized story about them. And so, that somehow we had to make the case that sitting with the discomfort of the disagreement, even if it didn't mean problem solving, although we hope for that, even if we didn't mean that it was worthwhile and it was important. And so, part of what was really attractive to me about joining up with Joel is that he just brought all of this brain science aspect to it that I had this kind of teaching and kind of academic in the negotiation and dispute resolution research experience, but couldn't bring to bear the kind of brain science parts of, well, what is going on in our brain when we do want to run or when we get into that really unproductive battle.

Eric Topol (06:27):

Yeah, I agree that the unique part here is that whole scaffolding with the neuroscience, the behavioral science, and those five Fs that you mentioned. You alluded to fight, flight, freeze, fawn, or fester. Yeah, so avoidance of conflict has kind of been the default for many people now because we have political divides, we have anti-science versus pro-science divides and on and on. There's a quote in the book that I thought we'd start off with because it really lays the groundwork from you both. “The biggest hidden barrier to being conflict resilient stems from the inability or unwillingness to face and sit with our own internal conflicts - the negotiations between our divided and sometimes contradictory “selves.” Even more surprising is that although there are dozens of self-help books on negotiation and conflict resolution, almost none of them spend any meaningful time on this critical intrapersonal barrier to handing conflict.” So maybe Joel, maybe start you off here. I guess you were bullied as a kid, and maybe that gives you a little background here. Joel, tell us about that if you would.

Bob Bordone (07:46):

Hey, Eric. On our bad days sometimes I probably inadvertently bully Joel still today, but he's pretty resilient now.

Joel Salinas (07:53):

Yeah, I'm a Teflon. So I think I am generally conflict of what an individual, and I think a lot of listeners and viewers can relate with that experience. And I think that also kind of speaks to some of the neuroscience that comes into this, which is that our brain has really evolved to be a fortune telling machine. It takes all of our past experiences, turns them into memories, and then makes projections about what's going to happen. And this projection or prediction of what's going to happen might as well be reality for our brain's sake. And so, if we had really negative experiences with conflict in the past growing up, whether through our families or the schoolyard or others, there'll…



Get full access to Ground Truths at erictopol.substack.com/subscribe
Steve Quake and Charlotte Bunne: The Holy Grail of Biology18 mars 202500:43:43

“Eventually, my dream would be to simulate a virtual cell.”—Demis Hassabis

The aspiration to build the virtual cell is considered to be equivalent to a moonshot for digital biology. Recently, 42 leading life scientists published a paper in Cell on why this is so vital, and how it may ultimately be accomplished. This conversation is with 2 of the authors, Charlotte Bunne, now at EPFL and Steve Quake, a Professor at Stanford University, who heads up science at the Chan-Zuckerberg Initiative

The audio (above) is available on iTunes and Spotify. The full video is linked here, at the top, and also can be found on YouTube.

TRANSCRIPT WITH LINKS TO AUDIO

Eric Topol (00:06):

Hello, it's Eric Topol with Ground Truths and we've got a really hot topic today, the virtual cell. And what I think is extraordinarily important futuristic paper that recently appeared in the journal Cell and the first author, Charlotte Bunne from EPFL, previously at Stanford’s Computer Science. And Steve Quake, a young friend of mine for many years who heads up the Chan Zuckerberg Initiative (CZI) as well as a professor at Stanford. So welcome, Charlotte and Steve.

Steve Quake (00:42):

Thanks, Eric. It's great to be here.

Charlotte Bunne:

Thanks for having me.

Eric Topol (00:45):

Yeah. So you wrote this article that Charlotte, the first author, and Steve, one of the senior authors, appeared in Cell in December and it just grabbed me, “How to build the virtual cell with artificial intelligence: Priorities and opportunities.” It's the holy grail of biology. We're in this era of digital biology and as you point out in the paper, it's a convergence of what's happening in AI, which is just moving at a velocity that's just so extraordinary and what's happening in biology. So maybe we can start off by, you had some 42 authors that I assume they congregated for a conference or something or how did you get 42 people to agree to the words in this paper?

Steve Quake (01:33):

We did. We had a meeting at CZI to bring community members together from many different parts of the community, from computer science to bioinformatics, AI experts, biologists who don't trust any of this. We wanted to have some real contrarians in the mix as well and have them have a conversation together about is there an opportunity here? What's the shape of it? What's realistic to expect? And that was sort of the genesis of the article.

Eric Topol (02:02):

And Charlotte, how did you get to be drafting the paper?

Charlotte Bunne (02:09):

So I did my postdoc with Aviv Regev at Genentech and Jure Leskovec at CZI and Jure was part of the residency program of CZI. And so, this is how we got involved and you had also prior work with Steve on the universal cell embedding. So this is how everything got started.

Eric Topol (02:29):

And it's actually amazing because it's a who's who of people who work in life science, AI and digital biology and omics. I mean it's pretty darn impressive. So I thought I'd start off with a quote in the article because it kind of tells a story of where this could go. So the quote was in the paper, “AIVC (artificial intelligence virtual cell) has the potential to revolutionize the scientific process, leading to future breakthroughs in biomedical research, personalized medicine, drug discovery, cell engineering, and programmable biology.” That's a pretty big statement. So maybe we can just kind of toss that around a bit and maybe give it a little more thoughts and color as to what you were positing there.

Steve Quake (03:19):

Yeah, Charlotte, you want me to take the first shot at that? Okay. So Eric, it is a bold claim and we have a really bold ambition here. We view that over the course of a decade, AI is going to provide the ability to make a transformative computational tool for biology. Right now, cell biology is 90% experimental and 10% computational, roughly speaking. And you've got to do just all kinds of tedious, expensive, challenging lab work to get to the answer. And I don't think AI is going to replace that, but it can invert the ratio. So within 10 years I think we can get to biology being 90% computational and 10% experimental. And the goal of the virtual cell is to build a tool that'll do that.

Eric Topol (04:09):

And I think a lot of people may not understand why it is considered the holy grail because it is the fundamental unit of life and it's incredibly complex. It's not just all the things happening in the cell with atoms and molecules and organelles and everything inside, but then there's also the interactions the cell to other cells in the outside tissue and world. So I mean it's really quite extraordinary challenge that you've taken on here. And I guess there's some debate, do we have the right foundation? We're going to get into foundation models in a second. A good friend of mine and part of this whole I think process that you got together, Eran Segal from Israel, he said, “We're at this tipping point…All the stars are aligned, and we have all the different components: the data, the compute, the modeling.” And in the paper you describe how we have over the last couple of decades have so many different data sets that are rich that are global initiatives. But then there's also questions. Do we really have the data? I think Bo Wang especially asked about that. Maybe Charlotte, what are your thoughts about data deficiency? There's a lot of data, but do you really have what we need before we bring them all together for this kind of single model that will get us some to the virtual cell?

Charlotte Bunne (05:41):

So I think, I mean one core idea of building this AIVC is that we basically can leverage all experimental data that is overall collected. So this also goes back to the point Steve just made. So meaning that we basically can integrate across many different studies data because we have AI algorithms or the architectures that power such an AIVC are able to integrate basically data sets on many different scales. So we are going a bit away from this dogma. I'm designing one algorithm from one dataset to this idea of I have an architecture that can take in multiple dataset on multiple scales. So this will help us a bit in being somewhat efficient with the type of experiments that we need to make and the type of experiments we need to conduct. And again, what Steve just said, ultimately, we can very much steer which data sets we need to collect.

Charlotte Bunne (06:34):

Currently, of course we don't have all the data that is sufficient. I mean in particular, I think most of the tissues we have, they are healthy tissues. We don't have all the disease phenotypes that we would like to measure, having patient data is always a very tricky case. We have mostly non-interventional data, meaning we have very limited understanding of somehow the effect of different perturbations. Perturbations that happen on many different scales in many different environments. So we need to collect a lot here. I think the overall journey that we are going with is that we take the data that we have, we make clever decisions on the data that we will collect in the future, and we have this also self-improving entity that is aware of what it doesn't know. So we need to be able to understand how well can I predict something on this somewhat regime. If I cannot, then we should focus our data collection effort into this. So I think that's not a present state, but this will basically also guide the future collection.

Eric Topol (07:41):

Speaking of data, one of the things I think that's fascinating is we saw how AlphaFold2 really revolutionized predicting proteins. But remember that was based on this extraordinary resource that had been built, the Protein Data Bank that enabled that. And for the virtual cell there's no such thing as a protein data bank. It's so much more as you emphasize Charlotte, it's so much dynamic and these perturbations that are just all across the board as you emphasize. Now the human cell atlas, which currently some …



Get full access to Ground Truths at erictopol.substack.com/subscribe
Katelyn Jetelina: Public health in the US14 mars 202500:26:46

Thank you Katelyn Jetelina, Andy Meyers, Tracy Paeschke, MD, FACC, Bruce Lanphear, Tay MacIntyre, and many others for tuning into my live video with Katelyn Jetelina! Join me for my next live video in the app.



Get full access to Ground Truths at erictopol.substack.com/subscribe
Anna Greka: Molecular Sleuthing for Rare Diseases09 mars 202500:48:33

Funding for the NIH and US biomedical research is imperiled at a momentous time of progress. Exemplifying this is the work of Dr. Anna Greka, a leading physician-scientist at the Broad Institute who is devoted to unlocking the mysteries of rare diseases— that cumulatively affect 30 million Americans— and finding cures, science supported by the NIH.

A clip from our conversation

The audio is available on iTunes and Spotify. The full video is linked here, at the top, and also can be found on YouTube.

Transcript with audio and external links

Eric Topol (00:06):

Well, hello. This is Eric Topol from Ground Truths, and I am really delighted to welcome today, Anna Greka. Anna is the president of the American Society for Clinical Investigation (ASCI) this year, a very prestigious organization, but she's also at Mass General Brigham, a nephrologist, a cell biologist, a physician-scientist, a Core Institute Member of the Broad Institute of MIT and Harvard, and serves as a member of the institute’s Executive Leadership Team. So we got a lot to talk about of all these different things you do. You must be pretty darn unique, Anna, because I don't know any cell biologists, nephrologists, physician-scientist like you.

Anna Greka (00:48):

Oh, thank you. It's a great honor to be here and glad to chat with you, Eric.

Eric Topol (00:54):

Yeah. Well, I had the real pleasure to hear you speak at a November conference, the AI for Science Forum, which we'll link to your panel. Where I was in a different panel, but you spoke about your extraordinary work and it became clear that we need to get you on Ground Truths, so you can tell your story to everybody. So I thought rather than kind of going back from the past where you were in Greece and somehow migrated to Boston and all that. We're going to get to that, but you gave an amazing TED Talk and it really encapsulated one of the many phenomenal stories of your work as a molecular sleuth. So maybe if you could give us a synopsis, and of course we'll link to that so people could watch the whole talk. But I think that Mucin-1 or MUC1, as you call it, discovery is really important to kind of ground our discussion.

A Mysterious Kidney Disease Unraveled

Anna Greka (01:59):

Oh, absolutely. Yeah, it's an interesting story. In some ways, in my TED Talk, I highlight one of the important families of this story, a family from Utah, but there's also other important families that are also part of the story. And this is also what I spoke about in London when we were together, and this is really sort of a medical mystery that initially started on the Mediterranean island of Cyprus, where it was found that there were many families in which in every generation, several members suffered and ultimately died from what at the time was a mysterious kidney disease. This was more than 30 years ago, and it was clear that there was something genetic going on, but it was impossible to identify the gene. And then even with the advent of Next-Gen sequencing, this is what's so interesting about this story, it was still hard to find the gene, which is a little surprising.

Anna Greka (02:51):

After we were able to sequence families and identify monogenic mutations pretty readily, this was still very resistant. And then it actually took the firepower of the Broad Institute, and it's actually from a scientific perspective, an interesting story because they had to dust off the old-fashioned Sanger sequencing in order to get this done. But they were ultimately able to identify this mutation in a VNTR region of the MUC1 gene. The Mucin-1 gene, which I call a dark corner of the human genome, it was really, it's highly repetitive, very GC-rich. So it becomes very difficult to sequence through there with Next-Gen sequencing. And so, ultimately the mutation of course was found and it's a single cytosine insertion in a stretch of cytosines that sort of causes this frameshift mutation and an early stop codon that essentially results in a neoprotein like a toxic, what I call a mangled protein that sort of accumulates inside the kidney cells.

Anna Greka (03:55):

And that's where my sort of adventure began. It was Eric Lander’s group, who is the founding director of the Broad who discovered the mutation. And then through a conversation we had here in Boston, we sort of discovered that there was an opportunity to collaborate and so that’s how I came to the Broad, and that's the beginnings of this story. I think what's fascinating about this story though, that starts in a remote Mediterranean island and then turns out to be a disease that you can find in every continent all over the world. There are probably millions of patients with kidney disease in whom we haven't recognized the existence of this mutation. What's really interesting about it though is that what we discovered is that the mangled protein that's a result of this misspelling of this mutation is ultimately captured by a family of cargo receptors, they’re called the TMED cargo receptors and they end up sort of grabbing these misfolded proteins and holding onto them so tight that it's impossible for the cell to get rid of them.

Anna Greka (04:55):

And they become this growing heap of molecular trash, if you will, that becomes really hard to manage, and the cells ultimately die. So in the process of doing this molecular sleuthing, as I call it, we actually also identified a small molecule that actually disrupts these cargo receptors. And as I described in my TED Talk, it's a little bit like having these cargo trucks that ultimately need to go into the lysosome, the cells recycling facility. And this is exactly what this small molecule can do. And so, it was just like a remarkable story of discovery. And then I think the most exciting of all is that these cargo receptors turn out to be not only relevant to this one mangled misshapen protein, but they actually handle a completely different misshapen protein caused by a different genetic mutation in the eye, causing retinitis pigmentosa, a form of blindness, familial blindness. We're now studying familial Alzheimer's disease that's also involving these cargo receptors, and there are other mangled misshapen proteins in the liver, in the lung that we're now studying. So this becomes what I call a node, like a nodal mechanism that can be targeted for the benefit of many more patients than we had previously thought possible, which has been I think, the most satisfying part about this story of molecular sleuthing.

Eric Topol (06:20):

Yeah, and it's pretty extraordinary. We'll put the figure from your classic Cell paper in 2019, where you have a small molecule that targets the cargo receptor called TMED9.

Anna Greka (06:34):

Correct.

Expanding the Mission

Eric Topol (06:34):

And what's amazing about this, of course, is the potential to reverse this toxic protein disease. And as you say, it may have applicability well beyond this MUC1 kidney story, but rather eye disease with retinitis pigmentosa and the familial Alzheimer's and who knows what else. And what's also fascinating about this is how, as you said, there were these limited number of families with the kidney disease and then you found another one, uromodulin. So there's now, as you say, thousands of families, and that gets me to part of your sleuth work is not just hardcore science. You started an entity called the Ladders to Cures (L2C) Scientific Accelerator.

Eric Topol (07:27):

Maybe you can tell us about that because this is really pulling together all the forces, which includes the patient advocacy groups, and how are we going to move forward like this?

Anna Greka (07:39):

Absolutely. I think the goal of the Ladders to Cures Accelerator, which is a new initiative that we started at the Broad, but it really encompasses many colleagues across Boston. And now increasingly it's becoming sort of a national, we even have some international collaborations, and it's only two years that it's been in existence, so we're certainly in a growth m…



Get full access to Ground Truths at erictopol.substack.com/subscribe
Carl Zimmer: Air-Borne and the Big Miss With Covid28 févr. 202500:53:57

Before getting into this new podcast, have you checked out the recent newsletter editions and podcasts of Ground Truths?

—the first diagnostic immunome

—a Covid nasal vaccine update

—medical storytelling and uncertainty

—why did doctors with A.I. get outperformed by A.I. alone?

The audio is available on iTunes and Spotify.

The full video is embedded here, at the top, and also can be found on YouTube.

Transcript with links to Audio and External Links

Eric Topol (00:07):

Well, hello. It's Eric Topol with Ground Truths, and I am just thrilled today to welcome Carl Zimmer, who is one of the great science journalists of our times. He's written 14 books. He writes for the New York Times and many other venues of great science, journalism, and he has a new book, which I absolutely love called Air-Borne. And you can see I have all these rabbit pages tagged and there's lots to talk about here because this book is the book of air. I mean, we're talking about everything that you ever wanted to know about air and where we need to go, how we missed the boat, and Covid and everything else. So welcome, Carl.

Carl Zimmer (00:51):

Thanks so much. Great to be here.

A Book Inspired by the Pandemic

Eric Topol (00:54):

Well, the book starts off with the Skagit Valley Chorale that you and your wife Grace attended a few years later, I guess, in Washington, which is really interesting. And I guess my first question is, it had the look that this whole book was inspired by the pandemic, is that right?

Carl Zimmer (01:18):

Certainly, the seed was planted in the pandemic. I was working as a journalist at the New York Times with a bunch of other reporters at the Times. There were lots of other science writers also just trying to make sense of this totally new disease. And we were talking with scientists who were also trying to make sense of the disease. And so, there was a lot of uncertainty, ambiguity, and things started to come into focus. And I was really puzzled by how hard it was for consensus to emerge about how Covid spread. And I did some reporting along with other people on this conflict about was this something that was spreading on surfaces or was it the word people were using was airborne? And the World Health Organization said, no, it's not airborne, it's not airborne until they said it was airborne. And that just seemed like not quantum physics, you know what I'm saying? In the sense that it seemed like that would be the kind of thing that would get sorted out pretty quickly. And I think that actually more spoke to my own unfamiliarity with the depth of this field. And so, I would talk to experts like say, Donald Milton at the University of Maryland. I'd be like, so help me understand this. How did this happen? And he would say, well, you need to get to know some people like William Wells. And I said, who?

Eric Topol (02:50):

Yeah, yeah, that's what I thought.

Carl Zimmer (02:53):

Yeah, there were just a whole bunch of people from a century ago or more that have been forgotten. They've been lost in history, and yet they were real visionaries, but they were also incredibly embattled. And the question of how we messed up understanding why Covid was airborne turned out to have an answer that took me back thousands of years and really plunged me into this whole science that's known as aerobiology.

Eric Topol (03:26):

Yeah, no, it's striking. And we're going to get, of course, into the Covid story and how it got completely botched as to how it was being transmitted. But of course, as you go through history, you see a lot of the same themes of confusion and naysayers and just extraordinary denialism. But as you said, this goes back thousands of years and perhaps the miasma, the moral stain in the air that was start, this is of course long before there was thing called germ theory. Is that really where the air thing got going?

A Long History of Looking Into Bad Air

Carl Zimmer (04:12):

Well, certainly some of the earliest evidence we have that people were looking at the air and thinking about the air and thinking there's something about the air that matters to us. Aristotle thought, well, there's clearly something important about the air. Life just seems to be revolve around breathing and he didn't know why. And Hippocrates felt that there could be this stain on the air, this corruption of the air, and this could explain why a lot of people in a particular area, young and old, might suddenly all get sick at the same time. And so, he put forward this miasma theory, and there were also people who were looking at farm fields and asking, well, why are all my crops dead suddenly? What happened? And there were explanations that God sends something down to punish us because we've been bad, or even that the air itself had a kind of miasma that affected plants as well as animals. So these ideas were certainly there, well over 2,000 years ago.

Eric Topol (05:22):

Now, as we go fast forward, we're going to get to, of course into the critical work of William and Mildred Wells, who I'd never heard of before until I read your book, I have to say, talk about seven, eight decades filed into oblivion. But before we get to them, because their work was seminal, you really get into the contributions of Louis Pasteur. Maybe you could give us a skinny on what his contributions were because I was unaware of his work and the glaciers, Mer de Glace and figuring out what was going on in the air. So what did he really do to help this field?

Carl Zimmer (06:05):

Yeah, and this is another example of how we can kind of twist and deform history. Louis Pasteur is a household name. People know who Louis Pasteur is. People know about pasteurization of milk. Pasteur is associated with vaccines. Pasteur did other things as well. And he was also perhaps the first aerobiologist because he got interested in the fact that say, in a factory where beet juice was being fermented to make alcohol, sometimes it would spoil. And he was able to determine that there were some, what we know now are bacteria that were getting into the beet juice. And so, it was interrupting the usual fermentation from the yeast. That in itself was a huge discovery. But he was saying, well, wait, so why are there these, what we call bacteria in the spoiled juice? And he thought, well, maybe they just float in the air.

Carl Zimmer (07:08):

And this was really a controversial idea in say, 1860, because even then, there were many people who were persuaded that when you found microorganisms in something, they were the result of spontaneous generation. In other words, the beet juice spontaneously produced this life. This was standard view of how life worked and Pasteur was like, I'm not sure I buy this. And this basically led to him into an incredible series of studies around Paris. He would have a flask, and he'd have a long neck on it, and the flask was full of sterile broth, and he would just take it places and he would just hold it there for a while, and eventually bacteria would fall down that long neck and they would settle in the broth, and they would multiply in there. It would turn cloudy so he could prove that there was life in the air.

Carl Zimmer (08:13):

And they went to different places. He went to farm fields, he went to mountains. And the most amazing trip he took, it was actually to the top of a glacier, which was very difficult, especially for someone like Pasteur, who you get the impression he just hated leaving the lab. This was not a rugged outdoorsman at all. But there he is, climbing around on the ice with this flask raising it over his head, and he caught bacteria there as well. And that actually was pivotal to destroying spontaneous generation as a theory. So aerobiology among many, many other things, destroyed this idea that life could spontaneously burst into existence.

Eric Topol (08:53):

Yeah, no. He says ‘these gentlemen, are the germs of microscopic beings’ shown in the existence of microorganisms in the air. So yeah, amazing contribution. And …



Get full access to Ground Truths at erictopol.substack.com/subscribe
Emily Silverman: Storytelling, Uncertainty, and Humanity in Medicine09 févr. 202500:47:26

Before getting into this new podcast, have you checked out the recent newsletter editions of Ground Truths?

—how are gut microbiome drives sugar cravings

—the influence of sleep on brain waste clearance and aging

—the new findings of microplastics in the brain

—the surprise finding about doctors and A.I.

In this podcast with Dr. Emily Silverman, an internist and founder of The Nocturnists, an award winning podcast and live show, we discuss what inspired her in medicine, what led to her disillusionment, the essentiality of storytelling, of recognizing uncertainty, the limits of A.I., and promoting humanity in medicine. The audio is available on iTunes and Spotify. The full video is linked here, at the top, and also can be found on YouTube.

“Storytelling is medicine's currency. Storytelling is not just an act of self-healing; it may actually create better physicians.”—Emily Silverman

Transcript with links to audio and relevant publications, websites

Eric Topol (00:07):

Well, hello. This is Eric Topol with Ground Truths, and with me, I am delighted to welcome Dr. Emily Silverman, who is Assistant Volunteer Professor of Medicine at UCSF, an old training grounds for me. And we're going to talk about some of the experience she's had there and she is the Founder of the remarkably recognized podcast, The Nocturnists. It's more than a podcast folks. We'll talk about that too. So Emily, welcome.

Emily Silverman (00:40):

Thank you for having me.

Inspiration by Kate McKinnon

Eric Topol (00:42):

Yeah. Well, I thought I would go back to perhaps when we first synapsed, and it goes back to a piece you wrote in JAMA about going to the Saturday Night Live (SNL) with Kate McKinnon. And it was one of my favorite columns, of course, it brought us together kind of simpatico because you were telling a story that was very personal, and a surprise factor added to it. We'll link to it. But it said, ‘Sometime in 2016, I fell in love with SNL comedian Kate McKinnon.’ You wrote, ‘It was something about her slow-mo swagger; her unilateral dimple, flickering in and out of existence; the way she drinks up her characters and sweats them from her pores.’ I mean, you're an incredible writer, no less podcast interviewer, organizer, doctor. And you talked about my sterile clinical life, which was kind of maybe a warning of things to come and about the fact that there's two very different career paths, comedy and medicine. One could argue they are in essence the same. So maybe you could tell us about that experience and about Kate McKinnon who, I mean, she's amazing.

Emily Silverman (02:09):

You're making me blush. Thank you for the kind words about the piece and about the writing, and I'm happy to give you a bit of background on that piece and where it came from. So I was in my internal medicine residency at UCSF and about halfway through residency really found myself hitting a wall. And that is actually what gave birth to The Nocturnists, which is the medical storytelling program that I run. But I think another symptom of my hitting that wall, so to speak, and we can talk more about what exactly that is and what that means, was me really looking outside of medicine and also outside of my typical day-to-day routine to try to find things that were a part of me that I had lost or I had lost touch with those aspects of myself. And one aspect of myself that I felt like I had lost touch to was my humorous side, my sense of humor, my silly side even you could say.

Emily Silverman (03:17):

And throughout my life I have this pattern where when I'm trying to get back in touch with a side of myself, I usually find somebody who represents that and sort of study it, I guess you could say. So in this case, for whatever reason that landed on Kate McKinnon, I just loved the surrealism of her comedy. I loved how absurd she is and loved her personality and so many things. Everything that you just read and really found her and her comedy as an escape, as a way to escape the seriousness of what I was doing on a day-to-day basis in the hospital and reconnect with those humorous sides of myself. So that's the understory. And then the story of the article is, I happened to be traveling to New York for a different reason and found myself standing in line outside of 30 Rock, hoping to get into Saturday Night Live. And there was basically a zero chance that we were going to get in. And part of the reason why is the musical guest that week was a K-pop band called BTS, which is one of the most famous bands in the world. And there were BTS fans like camped out in three circles around 30 Rock. So that week in particular, it was especially difficult to get in. There was just too many people in line. And we were at the very end of the line.

Eric Topol (04:43):

And it was in the pouring rain, too.

Emily Silverman (04:45):

And it was pouring rain. And my husband, God bless him, was there with me and he was like, what are we doing? And I was like, I don't know. I just have a feeling that we should stay in line, just go with it. So we did stay in line and then in the morning we got a number, and the way it works is you get your number and then that evening you show up with your number and our number was some crazy number that we weren't going to get in. But then that evening when we went back with our number to wait in line again to get in, what ended up happening is a young woman in the NBC gift shop, she passed out in the middle of the gift shop and I was right there. And so, I went over to her and was asking her questions and trying to help her out.

Emily Silverman (05:27):

And fortunately, she was fine. I think she just was dehydrated or something, and the security guards were so appreciative. And the next thing I knew, they were sweeping me backstage and up a staircase and in an elevator and they said, thank you so much for your service, welcome to Saturday Night Live. So it became this interesting moment where the very thing that I had been escaping from like medicine and serving and helping people ended up being the thing that gave me access, back to that side of myself, the humorous side. So it was just felt kind of cosmic, one of those moments, like those butterfly wing flapping moments that I decided to write about it and JAMA was kindly willing to publish it.

Eric Topol (06:15):

Well, it drew me to you and recognize you as quite an extraordinary talent. I don't know if you get recognized enough for the writing because it's quite extraordinary, as we'll talk about in some of your other pieces in the New York Times and in other JAMA journals and on and on. But one thing I just would note is that I resort to comedy a lot to deal with hard times, like the dark times we're in right now, so instead of watching the news, I watch Jimmy Kimmel's monologue or Colbert's monologue or the Comedy Show, anything to relieve some of the darkness that we're dealing with right at the moment. And we're going to get back to comedy because now I want to go back, that was in 2019 when you wrote that, but it was in 2016 when you formed The Nocturnists. Now, before you get to that critical path in your career of this new podcast and how it blossomed, how it grew is just beyond belief. But maybe you could tell us about your residency, what was going on while you were a medical resident at UCSF, because I can identify with that. Well, like any medical residency, it's pretty grueling experience and what that was like for you.

Medical Residency

Emily Silverman (07:45):

There were so many wonderful positive aspects of residency and there were so many challenges and difficult aspects of residency. It's all mixed up into this sticky, complicated web of what residency was. On the positive side, some of the most amazing clinicians I've ever met are at UCSF and whether that was seasoned attendings or chief residents who they just seemed to have so many skills, the clinical, the research, the teaching, just amazing, amazing high caliber people to learn from. And of cours…



Get full access to Ground Truths at erictopol.substack.com/subscribe
Lotte Bjerre Knudsen: The Scientist Who Drove GLP-1 Drugs For Obesity and Alzheimer's 04 janv. 202500:47:05

The Chief Scientific Advisor at Novo Nordisk, Lotte Bjerre Knudsen, was the key force who pushed hard to develop GLP-1 drugs for treating obesity and subsequently for Alzheimer’s. She was recently recognized by the 2024 Lasker Medical Research Award, and the 2024 AAAS Bhaumik Breakthrough of the Year Award. That recognition is richly deserved, since it is unclear if the GLP-1 drug path to obesity treatment, and all of the associated benefits, would have been seen at this time without her influence. That’s especially true given the mystery for why people with Type 2 diabetes (for which these drugs were used for many years) did not exhibit much in the way of weight loss. We discussed that and the future of these drugs, including their potential to prevent neurodegenerative diseases. And about dressing up in pink!

The Ground Truths podcasts are also available on Apple and Spotify.

Our entire conversation can also be seen by video at YouTube along with all of the Ground Truths podcasts. If you like the video format, please subscribe to this channel. Even if you prefer video, please take a look at the transcript with graphics and useful links to citations.

A Video Clip below on the barriers of a woman scientist to push Novo Nordisk to develop GLP-1 for obesity.

“I was always just been a nerdy little scientist who kind of found home here in this company for 35 years.”—Lotte Bjerre Knudsen, 60 Minutes

Transcript with Links to audio and external references

Eric Topol (00:06):

Well, hello, it's Eric Topol with Ground Truths, and I have with me a special guest. She's the Chief Science Officer of Novo Nordisk and it's Lotte Bjerre Knudsen, and we're delighted to have her. She's a recent recipient of the Lasker Award, which I think is considered like the pre-Nobel Award here in the United States. And I was involved with her in terms of researching who was the principal person who brought the GLP-1 drugs to the forefront for obesity, and it turned out to be Lotte. So welcome, Lotte.

Lotte Bjerre Knudsen (00:48):

Thank you very much. And also very, very happy to be here. I'm not the Chief Science Officer for Novo Nordisk, I'm the Chief Scientific Advisor of working for the Chief Science Officer of Novo Nordisk, but maybe too many people, not so different, right?

From Laundry Detergents to GLP-1 Drugs

Eric Topol (01:06):

Yes. Thank you, I actually meant to say advisor, but yes, I'm glad you cleared that up. I know from speaking to some of your colleagues, I actually spoke to Robin yesterday that you are looked to very highly, the most highly regarded person in science there, so not surprisingly. What I want to do is first talk about the glucagon-like peptide-1 (GLP-1) that got its legs back in, I guess 1984. So we're going way back. And what's also interesting is that you go way back at Novo Nordisk to 35 years in 1989. And so, there had been this work with this extraordinary hormone and neurotransmitter with a very short half-life that you knew about. But when you first started in Novo Nordisk, you weren't working on this. As I understand it, you're working on laundry detergent enzymes. How did you make this pivot from the laundry enzymes to getting into the GLP-1 world?

Lotte Bjerre Knudsen (02:16):

Yeah, thank you for that question. I'm from the technical University of Denmark, so I'm trained in biotechnology, and we're a small country, so not that many companies to work for. And I always had my mind set on, I wanted to work for Novo as it was called back then, and it just happened to be in the industrial enzyme part that I got my foot in first. And then I had a very interesting boss at the time. Unfortunately, he's not alive anymore, but he was both a medical doctor as well as a chemist. So he was actually put in charge of actually, let's see if we can do something new in diabetes. And then since he hired me and I had not been there that long, I simply tagged along as the youngest scientist on the team, and then suddenly I became a diabetes researcher. Around the same time, I think you remember that all of pharma was interested in obesity in the early 90s, everyone wanted to do diabetes as well as obesity, but they were separate teams and they all wanted to do small molecules, but it just happens to be so that the best idea we could find at that time was actually GLP-1, because we actually had clinical data relatively early that GLP-1 was a really good candidate as a treatment for diabetes because of the glucose sensitivity of the actions.

(03:43):

So you'd have efficient lowering of glucose through a dual mechanism with increasing insulin, lowering glucagon, and then it was safe because there wasn't this hypoglycemia you get from insulin. But then I had other colleagues who were working on obesity, and I was just kind of listening, right, what's going on there? And then also a colleague that I had, we had, I don’t know if you remember the old Hagedorn Research Institute, but Novo actually had kind of like an academic research institute that was affiliated with us. And there was this group that were working on this glucagon tumor model that produced high levels of glucagon, GLP-1 and PYY. And these rats, they starved themselves to death. And I knew about that from 1994. So that actually inspired my thinking. So when Stephen Bloom's paper came out in January of 1996, and he was the first one to call GLP-1 a neurotransmitter, I think, but I was already way into actually screening these kind of molecules that later then became liraglutide.

No One Else Thought About This [Obesity]

(04:54):

And then I thought, why on earth should we not actually do both things at the same time? If we have an idea that can both work in diabetes in a much safer way than in insulin, and then also at the same time work in obesity. But the reality is that no one else thought about this, or if they thought about it, they didn't really think that it would a good idea. But I think I had the luxury of being in a biotech company, so everyone was working with peptides and proteins. So I don't think I got the same challenge that the other people in the other pharma’s got when they all wanted small molecules.

Eric Topol (05:36):

Well, also just to set the foundation here, which you alluded to, there had been so many attempts to come up with a drug that would work, not just of course in diabetes where there are many classes of drugs, but moreover, to treat the condition of obesity. Actually, I was involved with one of them, Rimonabant and did the large trial, which as you know, led to having to stop the drug, discontinue it because it was associated with suicidal ideation and actual some suicide. So there had been such a long history of checkered inability to come up with a drug. But what was striking is the challenge, and this is one of the first important questions about, when you had the extended half-life of the first GLP-1 drug, that instead of having to take multiple times a day, you could actually, with liraglutide get to a point where you were starting to get to an extended half-life. This is now going back to 1997 with approval in 2010, still 14 years ago. But when you came up with this drug, because this was certainly one of your great contributions, this drug was just a step along the way in this kind of iterative process, wouldn't you say? It wasn't the long half-life and the potency that eventually got us to where we are today. Is that true?

Lotte Bjerre Knudsen (07:15):

Yeah, it was a stepwise process. And what's super interesting about this class of medicines is that they're actually so different. If you talk about a class of medicine where small molecules, they can be different, but they're usually more alike than they're different. And when it comes to this class with these medium-sized peptides, people tried a whole bunch of different things. So they're actually really, really different. Some are simple peptides. So the idea that I came up with was to use this fatty acid isolation principle, and t…



Get full access to Ground Truths at erictopol.substack.com/subscribe
Ardem Patapoutian: The Pervasive PIEZO Channels29 déc. 202400:39:58

Piezo touch and pressure-sensing ion channels are showing up everywhere as the explanation for physiologic phenomena, both at the macro and micro levels. Ardem Patapoutian, my friend and colleague at Scripps Research, discovered these receptors back in 2010 and was awarded the Nobel Prize in 2021 for his work. As you’ll see/hear from our conversation, the field has exploded. And you’ll get to know Ardem, who is such a fun, charismatic, and down-to-earth person. He also recently got a unique tattoo (videos below) and I wonder (unlikely) if any other Nobel laureates have one related to their discovery?!

Below is a video clip from our conversation. Full videos of all Ground Truths podcasts can be seen on YouTube here. The current one is here. If you like the YouTube format, please subscribe! The audios are also available on Apple and Spotify.

Transcript with links to audio

Eric Topol (00:07):

Well, hello. It's Eric Topol with Ground Truths, and I've really got a special guest today. The first time for the podcast, I've been able to interview a colleague and faculty at Scripps Research, Ardem Patapoutian, who just by the way happens to be the 2021 Nobel Laureate in Physiology or Medicine. So welcome, Ardem. It's so wonderful to have you.

Ardem Patapoutian (00:30):

Thanks so much, Eric. Looking forward to chatting with you.

Eric Topol (00:34):

Well, this has been interesting because although I've known you for several years, I didn't research you. I mean, I had to learn about more than I even do. And of course, one of the great sources of that is on the Nobel Prize website where you tell your whole story. It is quite a story and not to review all of it, but I wanted to go back just before you made the call to move to Los Angeles from Beirut, Lebanon and with the scare that you went through at that time, it seemed like that was just extraordinary that you had to live through that.

Ardem Patapoutian (01:11):

Yeah, so I am of Armenian origin, but I was born in Lebanon and born in 1967, so I was eight years old when the civil war started. So it's a kind of bizarre childhood in the sense that with all the bombs and fighting in Lebanon. So it was tough childhood to have, but it was never personal. It was bombs and such. And so, the event you're talking about is, I happened to be kidnapped while crossing East to West Beirut. They only held me for four or five hours at first asking me questions to see who I am, but I think they pretty soon figured out that I was not a dangerous guy and they ended up letting me go. But before that, that incident really had a huge impact on me so that by the time I got home, I literally said, I'm out of here. I'm going to find a way to leave the country. And so, that's what, very quickly within a few months I packed and came to United States.

Eric Topol (02:19):

And how did you pick LA to be your destination?

Ardem Patapoutian (02:22):

Being from the Armenian community, there's a lot of Armenians in Los Angeles. My cousins already had moved there. They also grew up in Lebanon. And my brother, who's a few years older than me, got admitted to USC graduate school in engineering. So he was going to be there. So it made a lot of sense.

Eric Topol (02:44):

Oh yeah.

Ardem Patapoutian (02:45):

Unlike him, I came with no school or job prospects because it happened so fast that I kind of just left. One year I was at American University of Beirut for one year, but then just left and came here. So worked for a year in various jobs and then started going back to school to UCLA.

Eric Topol (03:07):

Yeah, I saw how there was about a year where you were delivering pizzas and before you got into UCLA, and that must have been an interesting off year, if you will. Well, the story of course, just to fast forward, you did your baccalaureate at UCLA, your PhD at Caltech, postdoc at UCSF, and then you came to Scripps Research 24 years ago along with Pete Schultz, and it's been quite an amazing run that you've had. Now, before we get into PIEZO receptors, the background, maybe you could help me understand, the precursor work seems to be all related to the transient receptor potential (TRP) series, also ion channels. They were of course related to whether it was heat and temperature or somatosensory. How do these channels compare to the ones that you discovered years later?

Background on these Ion Channels

Ardem Patapoutian (04:09):

Yeah, so the somatosensory neurons that innervate your fingertips and everywhere else in your body, their main job is to sense temperature and pressure. And this is very different than any other neuron or any other cell. So when you touch a hot stove that’s burning hot, you need to know about that immediately within milliseconds or something cold. So the opposite side of it is pressure sensing, and it also comes in light touch, which is pleasant or a hammer hitting your finger, which is unpleasant. But all of these have the same characteristic anyway, that is your body has learned at the molecular level to translate a physical stimulus such as temperature and pressure into an electrical signal that neurons use to communicate with each other. But this idea of how you translate physical stimuli into chemical or electrical signal has been a long open question because as you know, most of our cells communicate by chemicals, whether that's hormones or small molecules, we know how that works, receptor bind to ligand, confirmational change and you get a kinase activation and that's enough. But here, how do you sense pressure? How do you sense temperature? It was just, there wasn't much known about that. And that's why our earlier work on TRP channels, which were temperature sensors came before the pressure. And so, they're very related in that sense.

Eric Topol (05:52):

The structure of these, if you were to look at them, do they look pretty similar? What the TRP as you say, and what you did back in the 2010 Science paper, which we'll link to, of course the classic paper where you describe PIEZO1 and PIEZO2, but if you were to look at this structures, would they look pretty similar?

Ardem Patapoutian (06:14):

No, that's a good question. And they absolutely don't. That's why finding these receptors were so hard. So if you go back to other sensory receptors, vision rhodopsin G-protein coupled receptor (GPCRs), larger G-protein coupled receptor look the same. So for example, when it was identified by chemically, that smell also works through G-protein coupled receptor. Richard Axel and Linda Buck, who also won the Nobel Prize, found those receptors by homology to visual GPCRs. The ion channels other than the fact that they crossed the membrane a few times or more, they have nothing else in common. If you looked at their structure, you can't even immediately tell they’re ion channels. So you couldn't find these by structural homology or sequence homology. So you had to do something else. And usually that means functional screens and et cetera.

Eric Topol (07:09):

Well, yeah, and I'm in touch with the screening. We'll get to that and how you dig these up and find them. But the somatosensory ones are really interesting because I don't think a lot of people realize that when you have wasabi or you have Listerine mouthwash and feel the burn and that these are all mediated through these channels, right?

Ardem Patapoutian (07:35):

Yeah. So there's this whole field of chemesthesis, which means senses in your mouth, for example, that are not explained by taste transduction and olfactory. And these are actually by the same somatosensory neurons that help you sense temperature and pressure. And some of these receptors are the same. Their evolution has taken over and used them for many different things. The prime example of this is the capsaicin receptor that David Julius my co-laureate identified, which is also heat receptors. So all languages describe chili peppers as hot, and that's not a coincidence. It actually activates heat activated channel, and that's why we think …



Get full access to Ground Truths at erictopol.substack.com/subscribe
© My Podcast Data · Independent project · Data from Apple & Spotify